INTERNATIONAL CANCER IMAGING SOCIETY

England & Wales · Charity number 1082082

Details

Other names	ICIS
Status	Registered
Legal form	Charitable company
Company number	03908709
Registered	2000-08-18
Register	View on the Charity Commission register

Contact

Address	41 Waddington Way London SE19 3UB
Phone	07956473369
Email	admin@cancerimagingsociety.org.uk
Website	icimagingsociety.org.uk

Activities

Objects: THE ADVANCEMENT OF EDUCATION AND RESEARCH WITHIN THE FIELD OF ONCOLOGICAL IMAGING AND HUMAN TUMOUR BEHAVIOUR WORLDWIDE INCLUDING IN PARTICULAR: (1) THE INTEGRATION OF CROSS SECTIONAL IMAGING TECHNIQUES, INCLUDING COMPUTED TOMOGRAPHY, MAGNETIC RESONANCE IMAGING, ULTRASONOGRAPHY AND NUCLEAR MEDICINE TECHNIQUES, CONVENTIONAL RADIOLOGY AND DEVELOPING AND NEW IMAGING MODALITIES (2) THE STUDY AND ANALYSIS OF THE EFFICACY AND OUTCOME OF DIAGNOSTIC IMAGING STUDIES (3) THE PROMOTION OF INTEREST IN ONCOLOGY AND THE FACILITATION OF EXCHANGE OF IDEAS BY THE ORGANISATION OF SCIENTIFIC MEETINGS, MULTICENTRE RESEARCH STUDIES, SEMINARS AND CONFERENCES ON ONCOLOGICAL IMAGING (4) THE PROVISION OF POST GRADUATE COURSES IN ONCOLOGICAL IMAGINING.

Activities: To promote education and research in cancer imaging and to foster its role in the multidisciplinary management of malignancy.

Downloaded from opencharities.uk/ew/1082082

Classification

- **How:** Makes Grants To Individuals
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups, The General Public/mankind

Geography

- **Area of benefit:** WORLDWIDE.
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-02-28	£186,231	£235,239	-	-
2024-02-29	£378,799	£288,778	-	-
2023-02-28	£321,405	£360,539	-	-
2022-02-28	£212,832	£173,830	-	-
2021-02-28	£115,469	£139,151	-	-

Downloaded from opencharities.uk/ew/1082082

Trustees

Name	Role	Appointed
Dr Anju Sahdev		2023-10-23
Dr Aslam Sohaib		2017-10-01
Dr Bachir Taouli		2024-10-12
Dr Celso Matos		2024-10-12
Dr EVIS SALA		2015-10-04
Dr Hersh Chandarana		2024-10-12
Dr MARY ELIZABETH McCARVILLE		2013-11-17
Dr ROSEMARIE FORSTNER		2016-11-21
Dr Thierry Andre Gerard Marie HUISMAN		2021-11-01
PROFESSOR DOW-MU KOH		2011-11-27
PROFESSOR GIOVANNI MORANA		2016-11-21
PROFESSOR HARRIET CAROLINA THOENY		
PROFESSOR RODNEY REZNEK		
PROFESSOR WILLEM OYEN		2016-11-21
Professor Annick Van Den Abbeele		2019-10-06
Professor Giuseppe PETRALIA		2021-11-01
Professor Olivier Robert LUCIDARME		2020-09-14
Professor Pek Lan KHONG		2021-11-01

Downloaded from opencharities.uk/ew/1082082

INTERNATIONAL CANCER IMAGING SOCIETY

England & Wales - Charity number 1082082

Accounts

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

28TH FEBRUARY 2025

Charity number 1082082
Company number 03908709

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

28TH FEBRUARY 2025

Contents **Page**

Report of the Trustees	1-10
Independent Examiner's Report	11
Statement of Financial Activities	12
Balance Sheet	13
Notes to the Accounts	14-19

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 28TH FEBRUARY 2025

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 28th February 2025.

The Board of Trustees is satisfied with the performance of the charity during the year, considers that the charity is able to continue its activities during the coming year and that the charity's assets are adequate to fulfil its obligations.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband
Prof. Rodney Reznek
Prof. Stefan Diederich
Prof. Anwar Padhani
Prof. Harriet Thoeny
Prof. Dow-Mu Koh
Prof. Andrea Rockall
Dr. Beth McCarville
Dr. Evis Sala
Prof. Willem Oyen
Dr. Rosemarie Forstner
Dr. Giovanni Morana
Dr. Aslam Sohaib
Prof. Rodney Hicks
Prof. Annick Van Den Abbeele
Prof. Olivier Lucidarme
Dr. Thierry Huisman
Prof. Pek Lan Khong
Prof. Giuseppe Petralia
Prof. Anju Sahdev
Dr Bachir Taouli (appointed 12 October 2024)
Dr Hersh Chandarana (appointed 12 October 2024)
Dr Celso Matos (appointed 12 October 2024)

The key management personnel are the trustees and General Manager. Maureen Watts and Anna Campbell have both served as General Manager at different times during the period.

Secretary and Registered Office Mr Trevor Pereira
41 Waddington Way
London
SE19 3UB

Registered Charity No: 1082082

Company Registration No: 03908709

Bankers Barclays Bank plc
9 Portman Square
London
W1A 3AL

Independent Examiners JCS Accountants Ltd
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Solicitors Weightmans LLP
100 Old Hall Street
Liverpool
L3 9QJ

Objects and Activities to achieve a public benefit

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

a) The integration of cross sectional imaging techniques, including computed tomography, magnetic resonance imaging, ultrasonography and nuclear medicine techniques, conventional radiology and developing new imaging modalities
b) The study and analysis of the efficacy and outcome of diagnostic imaging studies
c) The promotion of interest in oncology and the facilitation of exchange of ideas by the organisation of scientific meetings, multicentre research studies, seminars and conferences on oncological imaging
d) The provision of postgraduate courses in oncological imaging

The main activities undertaken by the Society to meet these objects are through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

Achievements and Performance

The shift in delegate preference for online learning has continued. While both in-person and online educational activities have continued to be offered to maintain the Society's status worldwide, the balance has continued to shift more towards online delivery. During this period two ICIS Interactive Masterclasses were delivered in-person but due to several factors, no in-person Masterclasses are planned for the 2025-2026 period. Early plans are for one in-person Masterclass in late 2026.

Online delivery of the ICIS Interactive Masterclass series continues to be well-received with the ever-popular whole-body MRI course continuing to sell-out whenever it is run. Plans are well-advanced for courses in 2025/2026 to be run on whole-body MRI, renal/adrenal imaging, head and neck imaging and prostate imaging. The Collective Minds Radiology (CMRAD) platform continued to be utilised for delivery of the masterclass workshops with an ongoing contract in place.

The bi-monthly webinars were re-established in 2024 to attract wider interest and to promote the Society's educational activities globally. The webinars remained free to watch live with subsequent posting on Society's YouTube channel. These have gone from strength to strength with each webinar attracting around 100 registrants and achieving a wide reach on YouTube. The success of the webinars will continue to provide a platform for growing the Society's reach and are a useful tool to widen awareness of upcoming ICIS Interactive Masterclasses.

The 2024 ICIS Annual Teaching Course was held in Singapore from 25–27 September 2024, marking a significant milestone as the Society's first annual conference in Asia. With the President for the 2024 course based in Singapore, the Trustees endorsed the proposal to expand the Society's global footprint through this regional venture. A formal collaboration agreement was established with the Singapore Radiological Society and the College of Radiologists Singapore, resulting in a joint event titled 'ICIS SGCR-WIRES 2024'. This partnership aimed to introduce ICIS to a broader audience and lay the groundwork for future collaborations across Asia.

The meeting, themed 'Illuminating Cancer Care: The evolving role of imaging and intervention in modern clinical practice', featured a multidisciplinary programme designed to deliver cutting-edge insights and updates to the international radiological, nuclear medicine, and allied health communities. The event was well received, with strong attendance and positive feedback from participants. The income from the meeting was shared between the organising bodies and generated a surplus for the Society of £27,000, further reinforcing the success of this inaugural Asian collaboration.

ICIS satellite meetings returned and a joint session with the Taiwanese Radiological Society during the 22nd Asian Oceanian Congress of Radiology (AOCR 2024) was held in March 2024 in Taiwan. A Society booth for ICIS was included in the AOCR exhibition, which enabled promotion of the 2024 annual conference in Singapore. Satellite activities are considered an important part of the Society's educational output to reach and teach colleagues around the globe; thus further potential partnerships with international contacts will continue to be explored.

Attendance at the Radiological Society of North America 2024 Annual Scientific Meeting (RSNA) in November 2024, with a complimentary Society booth was once again taken up after the decision not to attend in 2023. It once again proved to be a useful forum for increasing awareness of the society, promoting the 2025 annual teaching course and making connections with potential sponsors.

Improving international visibility of the Society and worldwide marketing of Society events has remained under constant review. Regular social media activity through a range of platforms ('X', LinkedIn, Instagram, Facebook, and YouTube) has disseminated information, supporting the monthly e-newsletter, mailings and advertising.

A new ICIS website has been built and will be updated regularly, providing current and accurate information with the aim of increasing membership, attendance at teaching courses and readership of 'Cancer Imaging', all with a view to strengthening the Society's profile, its outreach and influence, as well as generating income for the Society. All these channels enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.

'Cancer Imaging' has continued to be published by BioMed Central as an online open access journal. The Impact Factor (IF) released in June 2024 dropped from 4.9 to 3.5 following a reorganisation of how journal impact factors were collated. Other journals also saw a similar drop. Despite this, the journal continues to be ranked within the first quartile in Radiology journals and second quartile in Oncology journals, producing a 5-year IF of 4.3. The number of articles accessed continued to increase throughout the year, continuing to surpass 1 million during 2024.

Professor Rodney Hicks [Melbourne, Australia] and Professor Annick Van den Abbeele [Boston, USA] stood down as Joint Honorary Editors-in-Chief and were replaced by Professor Khaled Elsayes (Houston, USA). Dr Thorsten Persigehl [Cologne, Germany] continued as Deputy Editor and was joined by Katherine Krajewski (Boston, USA), Elaine Yuen Phin Lee (Hong Kong), Olivier Lucidarme (Paris, France). Section Editors and the Editorial Board worked with the pool of submission reviewers to maintain this important work in a timely manner, supporting the Editor-in-Chief and Deputy Editors to develop 'Cancer Imaging' further.

Society membership levels were closely monitored throughout the year, showing a slight decline compared to the previous year. This was attributed to the registration process for the 2024 Annual Teaching Course in Singapore, which, due to the joint nature of the event, was managed via an external platform rather than the ICIS website. As a result, the usual increase in membership associated with course registration was not realised. It is anticipated that this trend will reverse in 2025, when registrations will once again be processed directly through the ICIS website, reinstating the link between course participation and membership uptake.

While the increasing availability of free online educational resources presents some challenges in maintaining the perceived value of the Society's members-only archive, this has not significantly impacted overall engagement. Member retention remains an area of focus, and the Society continues to explore ways to enhance the value of membership through exclusive content, networking opportunities, and educational benefits.

At 28 February 2025, the number of Society members was 113 representing 35 countries worldwide; the number of Fellows was 86, representing 21 countries.

Structure, Governance and Management

The International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity, governed by its memorandum and articles of association.

The Society is governed by a Board of trustees that oversees the management of the activities which the charity runs. The charity trustees are also Directors of the Company limited by guarantee. Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow. Benefits of membership include reduced registration fees for Society teaching courses, access to the members' area of the website with its expanding repository of recorded lectures and scientific posters and a 20% discount on the article processing charge for accepted publications in *Cancer Imaging*.

During the period under review the Trustees convened online on two occasions, in March 2024 and September 2024, one week before the commencement of the annual teaching course. Day to day decisions and activities of the Society are delegated by the Trustees to the Executive Board.

The Trustees proposed revision of the articles of association to remove the automatic appointment of the journal's Editor-in-Chief as a Trustee. Voting by Fellows adopted this amendment in October 2024.

The Chair of the Executive Board reported to both Trustees' meetings, outlining the Board's ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. Meetings of the Executive Board were held in May, July and November 2024, and January 2025. These meetings were all conducted virtually enabling online participation of the internationally based Board members.

The Executive Board considers it judicious to maintain review of Society policies to ensure robust governance. The risk register is reviewed before each meeting to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk.

The activity implemented by the three sub-committees set up to oversee the ICIS Interactive programme, e-learning, and social media and communications is reviewed at each Executive Board meeting, ensuring a focus on opportunities to develop key elements of Society activity. Consideration is also given to the benefits of Society membership with the intention of retaining existing and attracting new members.

Compliance with the General Data Protection Regulations (GDPR) is maintained in line with the UK General Data Protection Regulation (UK GDPR 2021), tailored by the Data Protection Act 2018, and subject to monitoring by the Society registration with the Information Commissioner's Office.

Risks

Regular review of the risk register ensured continual monitoring of Society practices and activities to determine that anticipated benefit outweighed possible risk to the Society; maintaining income streams and promoting the Society worldwide remained a top priority. The replacement of the Society website and administration system continued to feature as an identified risk while the project got underway in June 2024 and continued throughout the year. The Society requires a viable, modern, robust structure from which to operate and expand, considering the financial implications or impact on Society reserves. The project proved challenging due to the complex nature of the requirements and variable levels of understanding of the developers. Issues have been addressed with the developers agreeing to shoulder some of the additional costs. The project will continue into the 2025-2026 period and will come in slightly over budget, but it is not expected to have a material impact on the Society's financial position.

Continued global interest in online educational activity in a very competitive virtual environment remained a challenge and risk to the Society. The Society's reputation as a provider of high-quality education on oncological imaging must be maintained; publication of high-quality research articles and reviews in 'Cancer Imaging' has retained the journal's international standing in its field. Enhancing the value of ICIS membership will mitigate the risk of lower member numbers, whose support is an integral element of the Society's continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series.

The Executive Board continued to consider potential natural disasters, international instability and terrorism as part of planning for in-person Society teaching courses, including any risk posed by infectious diseases, to report to the Trustees. The city and venue for each annual teaching course, or any in-person event, is chosen carefully with a request to include a break clause in the venue contract to mitigate potential risks should plans have to be changed. Insurance is reviewed every year.

The financial implications to the Society of any future satellite meetings will be carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of 'Cancer Imaging' will be kept under regular review.

Reference and administrative details

The Secretariat comprises two part-time employees, supported by contractors, who together maintain full and proper administrative control of all Society activities. During the period under review, the long-standing General Manager made the decision to retire and a new General Manager was appointed in May 2024. A six-month handover period was agreed and implemented.

Engagement of personnel continued with two-yearly renewable contracts, allowing for appropriate review, including salaries. ICIS does not have a central office facility for personnel; thus, overhead running costs are reduced; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters.

The project to replace the Society's website and administration system got underway in June 2024 with an initial completion target of Autumn 2024. However, due to the complexity of the requirements and challenges in translating these into technical specifications, the project timeline has extended into the current period. Significant difficulties were encountered in extracting and migrating data from legacy systems, and the high level of customisation required for the chosen open-source platform added further delays. Some aspects of the work exceeded the capabilities of the original development team, necessitating the recruitment of additional coders with specialised expertise. While the final cost of the project will exceed the original budget, this has been contained as much as possible thanks to the goodwill of the development partner, who agreed to absorb some of the additional costs arising from their own team's limitations and errors. Despite the setbacks, the project remains a strategic priority and is progressing steadily toward completion.

The Secretariat remained committed to enhancing engagement within the international radiology community to raise the profile of the Society, to encourage registration for teaching courses, to deliver successful courses and secure income for the continued functioning of the Society.

Financial Review

The Trustees and the Executive Board continued to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. Securing industry support for the Society and teaching activities in a less robust worldwide economic environment proved more challenging, whilst reduced income because of lower registration numbers created additional pressure on securing positive financial outcome.

The Society's corporate sponsorship package aims to secure financial commitment to the Society by industry leaders, The Executive Board recommended that three-year commitment should be sought for each new contract negotiated, with a view to facilitating robust financial planning and forecasting.

Siemens Healthineers, a machine manufacturing company, continued their support. Support from other companies continues to be explored as a second corporate sponsor would provide additional guaranteed income, to relieve some financial pressure.

Following the successful implementation of selling online access to content recorded at previous annual teaching courses, this was repeated and content of ICIS-SGCR-WIRES 2024 was made available for purchase as an online package with access until September 2025. Income generated offset the cost of providing this content, generated a small surplus and served as a marketing tool for other Society activity. Continued online delivery of the ICIS Interactive Masterclass series remained a valued source of income as preference was expressed by delegates for this format.

'Cancer Imaging' remained a notable element of the Society's overall success. Royalty payments based on revenue from published articles and an incentive bonus payment dependent on achievement of pre-determined targets both provided a beneficial income stream for the Society.

The Article Processing Charge (APC) is subject to annual review by the publisher. The Society has the option to apply a surcharge to the APC, the proceeds of which would provide direct additional income for the Society from each article published; however, it is judicious to consider the potential impact of a surcharge limiting the journal's attractiveness to authors, thereby reducing the number of submissions.

The Trustees had approved a budgeted deficit of £125,000 for the 2025 financial year, recognising the anticipated costs associated with the website redevelopment project and the strategic decision to hold the Annual Teaching Course in Asia for the first time, and as part of a joint meeting. This investment was considered a calculated risk to support the Society's long-term goal of expanding its reach and influence in the region. In the end, the actual deficit was significantly lower than forecast, closing at just £49,008. This positive variance was largely due to stronger-than-expected income from the Singapore meeting, both in terms of sponsorship and delegate registrations, as well as higher-than-budgeted revenue from the Society's journal. The outcome reflects prudent financial management and the success of the Society's efforts to broaden its international engagement.

The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation and remain optimistic that continued development of activities and worldwide promotion of the Society will assure a long-term future for the Society.

Reserves Policy

The reserves policy that was reviewed in 2023 to ensure compliance with current Charity Commission guidance remains in place. The annual teaching course is the Society's flagship event and primary income stream, representing significant financial undertaking for the Society. The Trustees remain committed to holding reserves sufficient to cover all potential costs in the event of a failed or aborted annual teaching course. Additional requirement for reserves identified in this period included unforeseen costs associated with replacement of the Society website/administrative system, an investment required to ensure future stability. Furthermore, the continued decline in industry support due to worldwide economic factors could necessitate use of reserves to maintain Society functions with potential increase in staff costs if additional cover were needed to support the small team.

The Society had unrestricted reserves of £347,016 that were not invested in fixed assets at the year end to February 2025; (2024: £395,911).

Plans for the future

On behalf of the Trustees, the Executive Board and sub-committees work to improve and expand the educational portfolio of the Society, to reach colleagues in the radiology community internationally and generate financial stability to permit further growth and development. The annual teaching course and the ICIS Interactive Masterclass workshop series are two key components of this strategy, in addition to attracting industry support, generating sufficient income to sustain the administrative structure and maintain reserves.

The Executive Board continues to believe that a combination of in-person and online courses provides the best balance of educational activity, and this balance will be maintained when programming future events, taking into account continued global economic pressures.

The 24th ICIS Annual Teaching Course will take place from 24–26 September 2025 at the Hague Conference Centre, The Netherlands. With Professor Thierry Huisman serving as Meeting President, the event marks a return to Europe following the Society's first Asian-based conference in 2024. The 2025 meeting is themed "Precision Diagnostics: Advancing Oncological Imaging Breakthroughs" and will bring together a distinguished international faculty of ICIS Fellows and global experts to deliver a comprehensive, multidisciplinary programme. The course will focus on the evolving role of precision imaging and image-guided interventions in oncology, with particular emphasis on imaging biomarkers, AI-driven diagnostics, and integrated clinical-radiological practice.

Following an invitation from Siemens Healthineers, the ICIS Interactive Masterclass on Gynaecological Cancers was conducted at their Academy facility in Warsaw, Poland, in May 2024. This was well received. Faculty and venue availability meant no further courses were scheduled there for the rest of the financial year, however, the ICIS Interactive Masterclass on Prostate Cancer is being planned for that venue in 2026. The ever-popular Masterclass in Whole-Body MRI was held online in July 2024; and a second course was run in-person in a venue in central Stockholm in November 2024. In 2025 Masterclasses in Rectal and Head & Neck Cancers will be delivered online and plans are well underway for a full programme in 2026.

The 'Read with the Experts' series originally launched in February 2023 focusing on hepatobiliary imaging would be re-run in the second half of 2025 as part of a collaboration with the Sao Paulo Radiology Society (SPR). A total of six segments would be delivered, five curated by ICIS Fellows and the sixth by a senior SPR member. The CMRAD platform would be utilised.

A further ICIS in Focus meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging was put on hold in 2025 due to staff capacity amid changes of personnel and the project to update the website and administration system. It is being considered for 2026, most likely as a partnership with Forth University in Heraklion, Crete. Ring-fenced funds following the 2023 ICIS in Focus course are available to support this initiative.

The Trustees have agreed that the 2026 annual teaching course will return to the United Kingdom following the usual pattern of being held in the UK every three years. The preferred location has been confirmed as Belfast, Northern Ireland which will represent the first annual teaching course to be held in Northern Ireland.

The series of bi-monthly webinars covering a variety of topics, planned by the e-learning committee, will continue as these generate substantial audiences with a wide geographical spread. Collaborations with other societies are considered to broaden the reach and establish relationships for future joint ventures.

A collaboration under the guidance of a Memorandum of Understanding with the Radiological Society of Sao Paulo (SPR) was finalised in September 2024 and was followed by a joint webinar in November 2024. Regular joint scientific sessions as part of the respective annual teaching course are planned for both the Journada Paulista de Radiologia in Sao Paulo in May 2025 and the ICIS annual course in The Hague in September 2025.

A similar collaboration with the Indian Radiological and Imaging Association (IRIA) was finalised in March 2025 following a joint scientific session at the Asian and Oceanic Congress of Radiology held jointly with IRIA in Chennai, India in January 2025.

Other international partners may be explored to expand the Society's worldwide reach.

Opportunities to establish further satellite meetings from 2025 are being explored with the first planned to be held in Oman in January 2026. These meetings present an opportunity to enhance the international profile of the Society, and enable radiologists in locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows.

An appraisal of any proposed satellite venue is reported to the Trustees to ensure no financial risk is posed to the Society, and Fellows representing the Society are not exposed to any personal risk. The Society does not cover any speaker expenses; these costs must be met by the host societies or personally.

Marketing Society activities and 'Cancer Imaging' will remain a priority; electronic means and social media enable enhanced communication with members and the wider international community with an interest in oncological imaging. The benefits of membership will be reviewed and assessment of options presented by online education to assist in promoting the Society and enhancing the appeal of membership. Google analytics of traffic to the ICIS website permits review of activity and the number of members will continue to be monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion. With the introduction of the new IT system, website analytics will be enhanced to inform on current activity and future developments.

A review of the overall Society strategy had been planned for late 2024 / 2025 to establish that Society activities and plans are relevant for the current requirements and expectations of the international radiological community and those embarking on a career in this specialist field. Due to changes in personnel and the website/administration system project, this was put on hold and will now be undertaken in late 2025/2026.

By order of the Board on 23 September 2025



Trevor Pereira
Secretary

INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF
INTERNATIONAL CANCER IMAGING SOCIETY

I report to the charity trustees on my examination of the accounts of the Company for the year ended 28th February 2025 set out on pages 12 to 19.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charites Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102)

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Paul Newton FCA
JCS Accountants Ltd
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Date:

INTERNATIONAL CANCER IMAGING SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account)
FOR THE YEAR ENDED 28TH FEBRUARY 2025

	Note	2025 Unrestricted Funds £	2025 Restricted Funds £	2025 Total £	2024 Unrestricted Funds £	2024 Restricted Funds £	2024 Total £
Income from:							
Charitable activities							
Conference sponsorship and funding		**54,280**	-	**54,280**	118,340	29,782	148,122
Revenue from conference delegates		**-**	-	**-**	146,938	-	146,938
Membership income		**20,752**	-	**20,752**	15,577	-	15,577
ICIS Interactives		**51,679**	-	**51,679**	30,504	-	30,504
Journal income		**51,684**	-	**51,684**	32,895	-	32,895
Interest receivable		**7,836**	-	**7,836**	4,763	-	4,763
Total income		**186,231**	-	**186,231**	349,017	29,782	378,799
Expenditure on:							
Charitable activities	2	**235,239**	-	**235,239**	272,066	16,712	288,778
Total expenditure		**235,239**	-	**235,239**	272,066	16,712	288,778
Net income/(expenditure) and movement in funds		**(49,008)**	-	**(49,008)**	76,951	13,070	90,021
Reconciliation of funds							
Total funds brought forward		**396,365**	**13,070**	**409,435**	319,414	-	319,414
Total funds carried forward		**347,357**	**13,070**	**360,427**	396,365	13,070	409,435

The notes on pages 14 to 19 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

BALANCE SHEET
AS AT 28TH FEBRUARY 2025

	Note	2025 £	2025 £	2024 £	2024 £
Fixed assets					
Tangible fixed assets	3		**341**		454
Current assets					
Debtors	4	**85,444**		41,871	
Cash at bank and in hand		**298,366**		393,118	
		383,810		434,989	
Creditors: Amounts falling due within one year	5	**23,724**		26,008	
Net current assets			**360,086**		408,981
Total Net assets less current liabilities			**360,427**		409,435
Funds					
Unrestricted funds	6		**347,357**		396,365
Restricted funds	7		**13,070**		13,070
Total Funds	8		**360,427**		409,435

These accounts have been prepared in accordance with the provisions available to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

For the financial year ended 28 February 2025 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements were approved by the Board on 23 September 2025 and signed on their behalf by:

Dr. Aslam Sohaib
Trustee

Prof. Dow Mu Koh
Trustee

Registered Charity No: 1082082

Company Registration No: 03908709

The notes on pages 14 to 19 form part of these financial statements.

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guaranteed registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

(b) Going concern

There are no significant uncertainties about the charity's ability to continue as a going concern.

(c) Income recognition

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

(d) Expenditure recognition

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

(e) Irrecoverable VAT

Irrecoverable VAT is included with the expense upon which it is incurred.

(f) Transactions in foreign currencies

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

(g) Tangible fixed assets

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)

1 ACCOUNTING POLICIES (CONTINUED)

(h) Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

(i) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation arising from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are recognised at their settlement amount

(j) Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 EXPENDITURE ON CHARITABLE ACTIVITIES

	Unrestricted Funds £	Restricted Funds £	Total 2025 £	Unrestricted Funds £	Restricted Funds £	Total 2024 £
Expenditure on						
Charitable activities						
Conference costs	**16,560**	**-**	**16,560**	85,916	9,950	95,866
Design, production and advertising	**3,540**	**-**	**3,540**	6,094	150	6,244
Administration						
- Staff costs (see note 9)	**91,174**	**-**	**91,174**	71,195	2,031	73,226
- Secretarial Services	**10,314**	**-**	**10,314**	6,665	1,700	8,365
- Other	**-**	**-**	**-**	2,500	-	2,500
Pension Scheme	**310**	**-**	**310**	284	-	284
Travel and accommodation	**24,189**	**-**	**24,189**	7,083	2,655	9,738
Printing	**1,863**	**-**	**1,863**	4,473	226	4,699
Bank charges and credit card charges	**1,294**	**-**	**1,294**	3,999	-	3,999
Insurance	**872**	**-**	**872**	654	-	654
Gifts and donations	**94**	**-**	**94**	1,185	-	1,185
Accreditations	**892**	**-**	**892**	353	-	353
Utilities	**161**	**-**	**161**	171	-	171
Postage/delivery charges	**2,322**	**-**	**2,322**	2,472	-	2,472
Telephone	**488**	**-**	**488**	525	-	525
Depreciation	**114**	**-**	**114**	152	-	152
Software expenses	**3,874**	**-**	**3,874**	1,119	-	1,119
IT support	**17,317**	**-**	**17,317**	27,885	-	27,885
Miscellaneous	**8**	**-**	**8**	-	-	-
Rent	**1,030**	**-**	**1,030**	1,020	-	1,020
Licenses and Permits	**8,253**	**-**	**8,253**	7,544	-	7,544
Accounting	**41,106**	**-**	**41,106**	39,889	-	39,889
Professional Fees	**1,224**	**-**	**1,224**	504	-	504
Independent Examiners fees	**2,316**	**-**	**2,316**	2,205	-	2,205
Foreign exchange losses/(gains)	**5,924**	**-**	**5,924**	(1,821)	-	(1,821)
	235,239	**-**	**235,239**	272,066	16,712	288,778

3 TANGIBLE FIXED ASSETS

	Computer Equipment	Total
	£	£
Cost		
As at 1st March 2024	1,150	1,150
Additions	-	-
Disposals	-	-
As at 28th February 2025	1,150	1,150
Depreciation		
As at 1st March 2024	695	695
Charge for year	114	114
Disposals	-	-
As at 28th February 2025	809	809
Net book value		
As at 28th February 2025	**341**	**341**
As at 29th February 2024	454	454

4 DEBTORS

	2025	2024
	£	£
Trade debtors	**12,430**	8,975
Prepayments and accrued income	**73,014**	32,896
	85,444	41,871

5 CREDITORS

	2025	2024
	£	£
Trade creditors	**3,801**	2,021
Accruals and deferred income	**19,923**	23,987
	23,724	26,008
Deferred income is included within:		
Current liabilities	3,455	-
Movement in the year:		
Deferred income at 1st March 2024	-	6,364
Released from previous periods	-	(6,364)
Resources deferred in the year	3,455	-
Deferred income at 28th February 2025	3,455	-

6 UNRESTRICTED FUNDS

	At 1st March 2024 £	Total Income £	Total Expenditure £	At 28th February 2025 £
Unrestricted Funds				
General Fund	396,365	186,231	(235,239)	347,357

	At 1st March 2023 £	Total Income £	Total Expenditure £	At 28th February 2024 £
Unrestricted Funds				
General Fund	319,414	349,017	(272,066)	396,365

7 RESTRICTED FUNDS

	At 1st March 2024 £	Total Income £	Total Expenditure £	At 28th February 2025 £
Restricted Funds				
AI Meeting	13,070	-	-	13,070

	At 1st March 2023 £	Total Income £	Total Expenditure £	At 29th February 2024 £
Restricted Funds				
AI Meeting	-	29,782	(16,712)	13,070

AI Meeting
This relates to funds received for the AI Meetings that started in 2023.

8 ANALYSIS OF NET ASSETS BY FUND

2025	Unrestricted £	Restricted £	Total £
Tangible fixed assets	341	-	341
Net current assets	347,016	13,070	360,086
	347,357	13,070	360,427

2024	Unrestricted £	Restricted £	Total £
Tangible fixed assets	454	-	454
Net current assets	395,911	13,070	408,981
	396,365	13,070	409,435

9 STAFF COSTS

	2025 £	2024 £
Salaries	**85,860**	69,444
Pension	**2,010**	1,709
Social security	**3,304**	2,073
	91,174	73,226
Average no. staff	**3**	2

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £47,904 (2024: £47,355). There were no other related party transactions in the year.

10 TRUSTEES' REMUNERATION

None of the trustees received any remuneration from the charity during the year (2024: none). Travel expenses incurred on behalf of the Society and reimbursed during the year to 28th February 2025 related to one trustee and amounted to £nil (2024: £1,500).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

11 LIMITED BY GUARANTEE

The company is limited by guarantee, each member (termed "Fellow" from October 2004) having guaranteed to pay £1 should the company be wound up.

INTERNATIONAL CANCER IMAGING SOCIETY

England & Wales - Charity number 1082082

Accounts

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

29TH FEBRUARY 2024

Charity number 1082082
Company number 03908709

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

29TH FEBRUARY 2024

Contents **Page**

Report of the Trustees	1-9
Independent Examiner's Report	10
Statement of Financial Activities	11
Balance Sheet	12
Notes to the Accounts	13-18

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 29TH FEBRUARY 2024

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 29th February 2024.

The Board of Trustees is satisfied with the performance of the charity during the year, considers that the charity is able to continue its activities during the coming year and that the charity's assets are adequate to fulfil its obligations.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband
Prof. Rodney Reznek
Prof. Stefan Diederich
Prof. Anwar Padhani
Prof. Harriet Thoeny
Prof. Dow-Mu Koh
Prof. Andrea Rockall
Dr. Beth McCarville
Dr. Evis Sala
Prof. Willem Oyen
Dr. Rosemarie Forstner
Dr. Giovanni Morana
Dr. Aslam Sohaib
Prof. Rodney Hicks
Prof. Annick Van Den Abbeele
Prof. Olivier Lucidarme
Dr. Thierry Huisman
Prof. Pek Lan Khong
Prof. Giuseppe Petralia
Prof. Anju Sahdev (appointed 23 October 2023)

The key management personnel are the trustees and Maureen Watts - General Manager.

Secretary and Registered Office Mr Trevor Pereira
41 Waddington Way
London
SE19 3UB

Registered Charity No: 1082082

Company Registration No: 03908709

Bankers Barclays Bank plc
9 Portman Square
London
W1A 3AL

Independent Examiners Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Solicitors Weightmans LLP
100 Old Hall Street
Liverpool
L3 9QJ

Objects and Activities to achieve a public benefit

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

a) The integration of cross sectional imaging techniques, including computed tomography, magnetic resonance imaging, ultrasonography and nuclear medicine techniques, conventional radiology and developing new imaging modalities
b) The study and analysis of the efficacy and outcome of diagnostic imaging studies
c) The promotion of interest in oncology and the facilitation of exchange of ideas by the organisation of scientific meetings, multicentre research studies, seminars and conferences on oncological imaging
d) The provision of postgraduate courses in oncological imaging

The main activities undertaken by the Society to meet these objects are through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

Achievements and Performance

Whilst the direct impact of the pandemic had waned with worldwide travel re-established, a definite shift in delegate preference for online learning was observed and it was noted that both in-person and online educational activities should be offered to maintain the Society's status worldwide.

The ICIS Interactive Masterclass workshop series in particular was affected by this shift and two new courses focusing on Head & Neck Cancers, and Current Topics in Renal & Adrenal Imaging, originally planned for classroom delivery, had to be postponed due to lack of registrations and re-scheduled for online delivery in November 2023 and January 2024 respectively. Other masterclass workshops conducted online during this period covered pancreatic malignancies, and whole-body MRI. A new initiative was trialled for the whole-body MRI workshop in conjunction with the South African Congress of Oncology (SACO), in Cape Town, with a hybrid delivery whereby one faculty member was onsite with the attendees and the other four faculty members joined via video link to present virtually. The workshop sold out very quickly and was very well-received by the onsite delegates; this model is likely to be repeated in the future. The Collective Minds Radiology (CMRAD) platform continued to be utilised for delivery of the masterclass workshops with an ongoing contract in place.

The postponed AI & Machine Learning 3.0 meeting was held in June 2023 in Lisbon, Portugal, in collaboration with the Champalimaud Foundation. Industry support was secured and a small exhibition included onsite which was well-received, and despite lower registration numbers than had been envisaged, a surplus was generated. This surplus will be ring-fenced with a view to exploring options for a future AI & Machine Learning meeting.

The 'Read with the Experts' series launched in February 2023 focusing on hepatobiliary imaging continued with four further segments conducted, each curated by an ICIS Fellow, utilising the CMRAD platform. Registrants had access to review cases and answer MCQs before a webinar was conducted to reveal the correct answers and the diagnosis. Whilst the number of participants of each segment was far fewer than originally hoped, a regular group of supporters of this series emerged. Upon conclusion of the final segment, the results were collated and prizes awarded to the two who had achieved the highest scores.

It was agreed that the bi-monthly webinars should be re-established in 2024 to attract wider interest and to promote the Society's educational activities globally. The first webinar in February 2024 was hosted jointly with an Australian prostate research consortium, providing an opportunity to promote the ICIS 2024 annual conference to be held in Singapore. The webinars remained free to watch live with subsequent posting in the ICIS members' area of the website or uploaded to the Society's YouTube channel.

The annual conference for 2023 was held in London, 25-27 September 2023, at the British Museum, London, utilising the deposit payment retained by the museum during the pandemic.

The meeting President, Professor Olivier Lucidarme, oversaw a successful three-day meeting, and whilst not on the scale of the previous annual conference held at the British Museum, very positive feedback was received from all participants and a significant financial surplus was generated.

Minimal activity with ICIS satellite meetings returned and in September 2023 five ICIS Fellows participated in the Korean Congress of Radiology (KCR), in Seoul. In addition, arrangements were confirmed for a joint session with the Taiwanese Radiological Society during the 22nd Asian Oceanian Congress of Radiology (AOCR 2024) to be held in March 2024 in Taiwan. A Society booth for ICIS will be included in the AOCR exhibition, which will enable promotion of the 2024 annual conference in Singapore. Satellite activities are considered an important part of the Society's educational output to reach and teach colleagues around the globe; thus further potential partnerships with international contacts will be explored to restart a programme of collaborations.

The opportunity to attend the Radiological Society of North America 2023 Annual Scientific Meeting (RSNA) with a complimentary Society booth was relinquished due to the planned attendance at AOCR 2024; an application will be made for RSNA 2024.

Improving international visibility of the Society and worldwide marketing of Society events has remained under constant review. Regular social media activity through a range of platforms ('X', LinkedIn, Instagram, Facebook, and YouTube) has disseminated information, supporting the monthly e-newsletter, mailings and advertising. The ICIS website has been updated regularly, providing current and accurate information with the aim of increasing membership, attendance at teaching courses and readership of 'Cancer Imaging', all with a view to strengthening the Society's profile, its outreach and influence, as well as generating income for the Society. All these channels enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.

'Cancer Imaging' has continued to be published by BioMed Central as an online open access journal. The Impact Factor (IF) released in June 2023 was a record 4.9, ranking the journal within the first quartile in Radiology journals (24/135) and second quartile in Oncology journals (78/241), producing a 5-year IF of 4.7. The number of articles accessed continued to increase throughout the year, surpassing 1 million during 2023.

Professor Rodney Hicks [Melbourne, Australia] and Professor Annick Van den Abbeele [Boston, USA] continued as Joint Honorary Editors-in-Chief. Dr Thorsten Persigehl [Cologne, Germany] succeeded Professor Stefan Diederich [Dusseldorf, Germany] as Deputy Editor. Section Editors and the Editorial Board worked with the pool of submission reviewers to maintain this important work in a timely manner, supporting the Editors-in-Chief to develop 'Cancer Imaging' further.

Society membership levels were monitored regularly but remained lower following the overall impact of the pandemic. Considerable volume of free online content is now widely available, potentially reducing the worth of archived Society material accessed as member-only content. A limited increase was achieved during the registration period for the London annual conference but retaining members remained a challenge, likely to be impacted further when registrations are handled externally during organization of ICIS 2024 in Singapore.

At 29 February 2024, the number of Society members was 136 representing 35 countries worldwide; the number of Fellows was 87 and one Associate Fellow, representing 21 countries.

Structure, Governance and Management

The International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity, governed by its memorandum and articles of association.

The Society is governed by a Board of trustees that oversees the management of the activities which the charity runs. The charity trustees are also Directors of the Company limited by guarantee. Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow. Benefits of membership include reduced registration fees for Society teaching courses, access to the members' area of the website with its expanding repository of recorded lectures and scientific posters and a 20% discount on the article processing charge for accepted publications in *Cancer Imaging*.

During the period under review the Trustees convened on two occasions, online in March 2023 by virtual means, and in a hybrid format in September 2023, on the day before the commencement of the annual teaching course. Day to day decisions and activities of the Society are delegated by the Trustees to the Executive Board.

The Trustees proposed revision of the articles of association to permit a non-Fellow to be appointed as Chair of the Executive Board, to ensure continued leadership of the Executive Board. Voting by Fellows adopted this amendment which states in addition that a Deputy Chair be appointed from the Fellowship on occasion of a non-Fellow Chair, to provide appropriate support. A new Bye-Law was introduced to set out terms of governance for the Executive Board.

The Chair of the Executive Board reported to both Trustees' meetings, outlining the Board's ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. Meetings of the Executive Board were held in April, July and November 2023, and January 2024. These meetings were all conducted virtually enabling online participation of the internationally based Board members.

The Executive Board considers it judicious to maintain review of Society policies to ensure robust governance. The risk register is reviewed before each meeting to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk.

The activity implemented by the three sub-committees set up to oversee the ICIS Interactive programme, e-learning, and social media and communications is reviewed at each Executive Board meeting, ensuring a focus on opportunities to develop key elements of Society activity. Consideration is also given to the benefits of Society membership with the intention of retaining existing and attracting new members.

Compliance with the General Data Protection Regulations (GDPR) is maintained in line with the UK General Data Protection Regulation (UK GDPR 2021), tailored by the Data Protection Act 2018, and subject to monitoring by the Society registration with the Information Commissioner's Office.

Risks

Regular review of the risk register ensured continual monitoring of Society practices and activities to determine that anticipated benefit outweighed possible risk to the Society; maintaining income streams and promoting the Society worldwide remained a top priority. The proposed replacement of the Society website and admin system underwent thorough review, to establish the most suitable provider to undertake the project. The Society requires a viable, modern, robust structure from which to operate and expand, taking into account the financial implications or impact on Society reserves.

Continued global interest in online educational activity in a very competitive virtual environment remained a challenge and risk to the Society. The Society's reputation as a provider of high-quality education on oncological imaging must be maintained; publication of high quality research articles and reviews in 'Cancer Imaging' has retained the journal's international standing in its field. Enhancing the value of ICIS membership will mitigate the risk of lower member numbers, whose support is an integral element of the Society's continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series.

The Executive Board continued to consider potential natural disasters, international instability and terrorism as part of planning for in-person Society teaching courses, including any risk posed by infectious diseases, such as variants of COVID-19, to report to the Trustees. The city and venue for each annual teaching course, or any in-person event, is chosen carefully with a request to include a break clause in the venue contract to mitigate potential risks should plans have to be changed. Insurance is reviewed every year.

The financial implications to the Society of any future satellite meetings will be carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of 'Cancer Imaging' will be kept under regular review.

Reference and administrative details

The Secretariat comprises two part-time employees, supported by contractors, who together maintain full and proper administrative control of all Society activities. During the period under review, additional administrative support was secured to ease the pressure on the existing personnel.

Engagement of personnel continued with two-yearly renewable contracts, allowing for appropriate review, including salaries. ICIS does not have a central office facility for personnel, thus overhead running costs are reduced; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters.

The web management company engaged in July 2022 identified instability in the outdated Society IT systems, recommending replacement within 18 months to two years. A project commenced to undertake a detailed review of the Society's requirements and invitations were put out to tender to companies considered suitable to undertake this important project. After thorough financial review of all proposals and due diligence, it is hoped that a replacement project will be started promptly with a view to completion by autumn 2024.

The Secretariat remained committed to enhancing engagement within the international radiology community to raise the profile of the Society, to encourage registration for teaching courses, to deliver successful courses and secure income for the continued functioning of the Society.

Financial Review

The Trustees and the Executive Board continued to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. Securing industry support for the Society and teaching activities in a less robust worldwide economic environment proved more challenging, whilst reduced income as a result of lower registration numbers created additional pressure on securing positive financial outcome.

The Society's corporate sponsorship package aims to secure financial commitment to the Society by industry leaders, The Executive Board recommended that three-year commitment should be sought for each new contract negotiated, with a view to facilitating robust financial planning and forecasting.

Siemens Healthineers, a machine manufacturing company, continued their support. The agreement with Guerbet, a contrast media company, has not currently been renewed for 2024 following their increased level of support for the ICIS 2023 annual course secured by the ICIS 2023 President. Support from other companies may be explored as a second corporate sponsor would provide additional guaranteed income, to relieve some financial pressure.

Following the successful implementation of selling online access to content recorded at the ICIS 2022 annual teaching course, this was repeated and content of ICIS 2023 was made available for purchase as an online package with access until September 2024. Income generated offset the cost of providing this content, generated a small surplus and served as a marketing tool for other Society activity.

Continued online delivery of the ICIS Interactive Masterclass series remained a valued source of income as preference was expressed by delegates for this format.

'Cancer Imaging' remained a notable element of the Society's overall success. Royalty payments based on revenue from published articles and an incentive bonus payment dependent on achievement of pre-determined targets both provided a beneficial income stream for the Society.

The Article Processing Charge (APC) is subject to annual review by the publisher. The Society has the option to apply a surcharge to the APC, the proceeds of which would provide direct additional income for the Society from each article published; however, it is judicious to consider the potential impact of a surcharge limiting the journal's attractiveness to authors, thereby reducing the number of submissions.

The Trustees are pleased to report that the overall outcome to the year ending 29 February 2024 is an increase of Society reserves, re-establishing a strengthened financial position. This has been achieved through support secured from industry, income generated from the 2023 annual teaching course and continued online delivery of ICISi masterclass workshops, alongside the stringent approach to control of Society expenditure.

The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation, and remain optimistic that continued development of activities and worldwide promotion of the Society will assure a long-term future for the Society.

Reserves Policy

The Trustees undertook a review of the Society's reserve policy to ensure compliance with current Charity Commission guidance. The annual teaching course is the Society's flagship event and primary income stream, representing significant financial undertaking for the Society. The Trustees remain committed to holding reserves sufficient to cover all potential costs in the event of a failed or aborted annual teaching course, and have agreed that reserves in the range of £200,000-£250,000 should be maintained. As the Trustees anticipate that the outturn to the 2024-25 financial year will be challenging, the availability of the reserves will help ensure the continuity of the Society. Additional requirement for reserves identified in this period included unforeseen costs associated with replacement of the Society website/administrative system, an investment required to ensure future stability. Furthermore, the continued decline in industry support due to worldwide economic factors could necessitate use of reserves to maintain Society functions with potential increase in staff costs if additional cover were needed to support the small team.

The Society had unrestricted reserves of £395,911 that were not invested in fixed assets at the year end to February 2024; (2023: £318,808).

Plans for the future

On behalf of the Trustees, the Executive Board and sub-committees work to improve and expand the educational portfolio of the Society, to reach colleagues in the radiology community internationally and generate financial stability to permit further growth and development. The annual teaching course and the ICIS Interactive Masterclass workshop series are two key components of this strategy, in addition to attracting industry support, generating sufficient income to sustain the administrative structure and maintain reserves.

The Executive Board has agreed that a combination of in-person and online courses provides the best balance of educational activity, and this balance will be maintained when programming future events, taking into account continued global economic pressures.

With the President for the annual teaching course in 2024 based in Singapore, the Trustees reviewed the proposal to conduct the first Asian annual conference. A collaboration agreement with the Singapore Radiological Society and College of Radiologists Singapore was signed to jointly organize and hold the annual conference in Singapore in September 2024. It was agreed that this joint venture would serve to introduce the Society to a new region and potentially establish links with other societies for future collaborations.

Entitled 'ICIS SGCR-WIRES 2024' to acknowledge the collaboration, the theme of the meeting will be 'Illuminating Cancer Care: The evolving role of imaging and intervention in modern clinical practice'. The multidisciplinary programme will be planned to provide valuable updates and insights for the international radiological, nuclear medicine and allied health communities, including the latest research and developments, highlighting the specialist field of cancer imaging and intervention.

Following an invitation from Siemens Healthineers, plans are in place to conduct the ICIS Interactive Masterclass on Gynaecological Cancers at their Academy facility in Warsaw, Poland, in May 2024. Other masterclasses have been held there successfully in the past and if well-received on this occasion, further courses will be scheduled. The ever-popular Masterclass in Whole-Body MRI will be held online in July 2024; a venue in central Stockholm is under review to potentially repeat this course in a classroom setting later in 2024. In 2025 the Masterclass in Head & Neck Cancers will be delivered online for the second time.

Discussions to assess feasibility of other new masterclass workshop topics include thoracic, hepatobiliary and rectal cancers; these new courses may be developed for delivery in 2025/2026.

A further *ICIS in Focus* meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging may be considered for 2025, pending review of suitable venues. Ring-fenced funds following the 2023 *ICIS in Focus* course are available to support this initiative.

The Trustees have agreed that the 2025 annual teaching course should return to Europe; the preferred location has been confirmed as The Hague, in The Netherlands.

The series of bi-monthly webinars covering a variety of topics, planned by the e-learning committee, will continue as these generate substantial audiences with a wide geographical spread. Collaborations with other societies are considered to broaden the reach and establish relationships for future joint ventures.

A collaboration under the guidance of a Memorandum of Understanding with the Brazilian Radiological Society (SPR) is under review with initial plans to organize regular joint scientific sessions as part of respective annual teaching courses. Similar collaborations with other international partners may be explored to expand the Society's worldwide reach.

It is hoped that opportunities can be explored to establish further satellite meetings from 2025. These meetings present an opportunity to enhance the international profile of the Society, and enable radiologists in locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows. The possibility of linking virtually with previous satellite partners may be explored, but potential online fatigue versus the value of in-person meetings will be factored into any decision.

An appraisal of any proposed satellite venue is reported to the Trustees to ensure no financial risk is posed to the Society, and Fellows representing the Society are not exposed to any personal risk. The Society does not cover any speaker expenses; these costs must be met by the host societies or personally.

Marketing Society activities and *'Cancer Imaging'* will remain a priority; electronic means and social media enable enhanced communication with members and the wider international community with an interest in oncological imaging. The benefits of membership will be reviewed and assessment of options presented by nline education to assist in promoting the Society and enhancing the appeal of membership. Google analytics of traffic to the ICIS website permits review of activity and the number of members will continue to be monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion. With the introduction of a new IT system, website analytics should be enhanced to inform on current activity and future developments.

A review of the overall Society strategy will be undertaken in late 2024 / 2025 to establish that Society activities and plans are relevant for the current requirements and expectations of the international radiological community and those embarking on a career in this specialist field.

By order of the Board on 26 September 2024



Trevor Pereira
Secretary

INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF
INTERNATIONAL CANCER IMAGING SOCIETY

I report to the charity trustees on my examination of the accounts of the Company for the year ended 29th February 2024 set out on pages 11 to 18.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charites Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102)

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Paul Newton FCA
Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Date: 15 October 2024

INTERNATIONAL CANCER IMAGING SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account)
FOR THE YEAR ENDED 29TH FEBRUARY 2024

	Note	2024 Unrestricted Funds £	2024 Restricted Funds £	2024 Total £	2023 Unrestricted Funds £	2023 Restricted Funds £	2023 Total £
Income from:							
Charitable activities							
Conference sponsorship and funding		118,340	29,782	148,122	202,957	-	202,957
Revenue from conference delegates		146,938	-	146,938	43,341	-	43,341
Membership income		15,577	-	15,577	21,299	-	21,299
ICIS Interactives		30,504	-	30,504	35,266	-	35,266
Journal income		32,895	-	32,895	16,575	-	16,575
Interest receivable		4,763	-	4,763	1,967	-	1,967
Total income		**349,017**	**29,782**	**378,799**	**321,405**	-	**321,405**
Expenditure on:							
Charitable activities	2	272,066	16,712	288,778	360,539	-	360,539
Total expenditure		**272,066**	**16,712**	**288,778**	**360,539**	-	**360,539**
Net income/(expenditure) and movement in funds		**76,951**	**13,070**	**90,021**	**(39,134)**	-	**(39,134)**
Reconciliation of funds							
Total funds brought forward		**319,414**	**-**	**319,414**	**358,548**	**-**	**358,548**
Total funds carried forward		**396,365**	**13,070**	**409,435**	**319,414**	**-**	**319,414**

The notes on pages 13 to 18 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

BALANCE SHEET
AS AT 29TH FEBRUARY 2024

	Note	2024 £	2024 £	2023 £	2023 £
Fixed assets					
Tangible fixed assets	3		454		606
Current assets					
Debtors	4	41,871		37,506	
Cash at bank and in hand		393,118		308,446	
		434,989		345,952	
Creditors: Amounts falling due within one year	5	26,008		27,144	
Net current assets			408,981		318,808
Total Net assets less current liabilities			409,435		319,414
Funds					
Unrestricted funds	6		396,365		319,414
Restricted funds	7		13,070		-
Total Funds	8		409,435		319,414

These accounts have been prepared in accordance with the provisions available to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

For the financial year ended 29 February 2024 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements were approved by the Board on 26 September 2024 and signed on their behalf by:

Dr. Aslam Sohaib
Trustee

Prof. Dow Mu Koh
Trustee

Registered Charity No: 1082082

Company Registration No: 03908709

The notes on pages 13 to 18 form part of these financial statements.

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guaranteed registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

(b) Going concern

There are no significant uncertainties about the charity's ability to continue as a going concern.

(c) Income recognition

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

(d) Expenditure recognition

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

(e) Irrecoverable VAT

Irrecoverable VAT is included with the expense upon which it is incurred.

(f) Transactions in foreign currencies

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

(g) Tangible fixed assets

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)

1 ACCOUNTING POLICIES (CONTINUED)

(h) Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

(i) Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation arising from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are recognised at their settlement amount

(j) Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 EXPENDITURE ON CHARITABLE ACTIVITIES

	Unrestricted Funds £	Restricted Funds £	Total 2024 £	Total 2023 £
Expenditure on				
Charitable activities				
Conference costs	85,916	9,950	95,866	190,472
Design, production and advertising	6,094	150	6,244	7,421
Administration				
- Data Manager	-	-	-	4,120
- Staff costs (see note 9)	71,195	2,031	73,226	72,560
- Secretarial Services	6,665	1,700	8,365	8,972
- Other	2,500	-	2,500	2,500
Pension Scheme	284	-	284	335
Travel and accommodation	7,083	2,655	9,738	15,806
Printing	4,473	226	4,699	6,377
Bank charges and credit card charges	3,999	-	3,999	2,601
Gifts and donations	1,185	-	1,185	100
Insurance	654	-	654	1,773
Accreditations	353	-	353	435
Utilities	171	-	171	226
Postage/delivery charges	2,472	-	2,472	529
Telephone	525	-	525	577
Depreciation	152	-	152	202
Software expenses	1,119	-	1,119	1,805
IT support	27,885	-	27,885	12,033
Miscellaneous	-	-	-	835
Rent	1,020	-	1,020	977
Licenses and Permits	7,544	-	7,544	553
Subscriptions	-	-	-	13
Accounting	39,889	-	39,889	38,918
Professional Fees	504	-	504	2,124
Consultancy Fee	-	-	-	300
Independent Examiners fees	2,205	-	2,205	2,079
Foreign exchange losses/(gains)	(1,821)	-	(1,821)	(14,104)
	272,066	16,712	288,778	360,539

3 TANGIBLE FIXED ASSETS

	Computer Equipment	Total
	£	£
Cost		
As at 1st March 2023	1,150	1,150
Additions	-	-
Disposals	-	-
As at 29th February 2024	1,150	1,150
Depreciation		
As at 1st March 2023	544	544
Charge for year	152	152
Disposals	-	-
As at 29th February 2024	696	696
Net book value		
As at 29th February 2024	454	454
As at 28th February 2023	606	606

4 DEBTORS

	2024	2023
	£	£
Trade debtors	8,975	22,820
Prepayments and accrued income	32,896	14,686
	41,871	37,506

5 CREDITORS

	2024	2023
	£	£
Trade creditors	2,021	1,899
Accruals and deferred income	23,987	25,245
	26,008	27,144
Deferred income is included within:		
Current liabilities	-	6,364
Movement in the year:		
Deferred income at 1st March 2023	6,364	145,153
Released from previous periods	(6,364)	(145,153)
Resources deferred in the year	-	6,364
Deferred income at 29th February 2024	-	6,364

6 UNRESTRICTED FUNDS

	At 1st March 2023 £	Total Income £	Total Expenditure £	At 29th February 2024 £
Unrestricted Funds				
General Fund	319,414	349,017	(272,066)	396,365

	At 1st March 2022 £	Total Income £	Total Expenditure £	At 28th February 2023 £
Unrestricted Funds				
General Fund	358,548	321,405	(360,539)	319,414

7 RESTRICTED FUNDS

	At 1st March 2023 £	Total Income £	Total Expenditure £	At 29th February 2024 £
Restricted Funds				
AI Meeting	-	29,782	(16,712)	13,070

AI Meeting
This relates to funds received for the AI Meetings that started in 2023.

8 ANALYSIS OF NET ASSETS BY FUND

2024	**Unrestricted £**	**Restricted £**	**Total £**
Tangible fixed assets	454	-	454
Net current assets	395,911	13,070	408,981
	396,365	13,070	409,435

2023	**Unrestricted £**	**Restricted £**	**Total £**
Tangible fixed assets	606	-	606
Net current assets	318,808	-	318,808
	319,414	-	319,414

9 STAFF COSTS

	2024 £	2023 £
Salaries	69,444	68,585
Pension	1,709	1,667
Social security	2,073	2,308
	73,226	72,560
Average no. staff	2	2

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £47,355 (2023: £49,505). There were no other related party transactions in the year.

10 TRUSTEES' REMUNERATION

None of the trustees received any remuneration from the charity during the year (2023: none). Travel expenses incurred on behalf of the Society and reimbursed during the year to 29th February 2024 related to one trustee and amounted to £1,500 (2023: £nil).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

11 LIMITED BY GUARANTEE

The company is limited by guarantee, each member (termed "Fellow" from October 2004) having guaranteed to pay £1 should the company be wound up.

INTERNATIONAL CANCER IMAGING SOCIETY

England & Wales - Charity number 1082082

Accounts

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

28TH FEBRUARY 2023

Charity number 1082082
Company number 03908709

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

28TH FEBRUARY 2023

Contents **Page**

Report of the Trustees	1-10
Independent Examiner's Report	11
Statement of Financial Activities	12
Balance Sheet	13
Notes to the Accounts	14-17

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 28TH FEBRUARY 2023

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 28th February 2023.

The Board of Trustees is satisfied with the performance of the charity during the year, considers that the charity is able to continue its activities during the coming year and that the charity's assets are adequate to fulfil its obligations.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband
Prof. Rodney Reznek
Dr. Conor Collins (resigned 26 October 2022)
Prof. Stefan Diederich
Prof. Anwar Padhani
Prof. Harriet Thoeny
Prof. Dow-Mu Koh
Prof. Andrea Rockall
Dr. Beth McCarville
Dr. Evis Sala
Prof. Willem Oyen
Dr. Rosemarie Forstner
Dr. Giovanni Morana
Dr. Aslam Sohaib
Prof. Rodney Hicks
Prof. Annick Van Den Abbeele
Prof. Olivier Lucidarme
Dr. Thierry Huisman
Prof. Pek Lan Khong
Prof. Giuseppe Petralia

The key management personnel are the trustees and Maureen Watts - General Manager.

Secretary and Registered Office Mr Trevor Pereira
41 Waddington Way
London
SE19 3UB

Bankers Barclays Bank plc
9 Portman Square
London
W1A 3AL

Independent Examiners Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Solicitors Radcliffes Le Brasseur
5 Great College Street
Westminster
London
SW1P 3SJ

Objects and Activities to achieve a public benefit

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

a) The integration of cross sectional imaging techniques, including computed tomography, magnetic resonance imaging, ultrasonography and nuclear medicine techniques, conventional radiology and developing new imaging modalities
b) The study and analysis of the efficacy and outcome of diagnostic imaging studies
c) The promotion of interest in oncology and the facilitation of exchange of ideas by the organisation of scientific meetings, multicentre research studies, seminars and conferences on oncological imaging
d) The provision of postgraduate courses in oncological imaging

The main activities undertaken by the Society to meet these objects are through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

Achievements and Performance

With the ongoing repercussions of the pandemic, educational activity continued to be conducted online for the first six months of this period. The series of bi-monthly webinars, first established in 2020, continued successfully by attracting significant interest and worldwide engagement with the Society. The webinars are free to watch live and subsequently available in the ICIS members' area of the website. A range of topics is covered, often providing the opportunity to promote forthcoming ICIS Interactive workshops or other Society activities.

Plans to conduct the postponed AI & Machine Learning meeting in Lisbon, Portugal, in May 2022 were reviewed and following due consideration, the decision was taken to postpone again with a view to holding the course in summer 2023.

The preference for delivering ICIS Interactive Masterclass workshops online remained in place with the gynaecological cancers course conducted in June 2022, selling out all 24 available places. On this occasion a new online radiology platform, Collective Minds Radiology (CMRAD), was utilised to deliver the workshop, with favourable feedback from both faculty and delegates. Individual access to the platform is enabled, allowing independent review of the workshop cases by each attendee. This success has translated into a longer-term relationship with CMRAD; a one-year contract was signed in February 2022, engaging their services throughout the coming year to conduct future ICISi masterclasses or other educational activities which can be adapted for delivery through the CMRAD platform.

As the effects and impact of the global pandemic waned, it was agreed that the 2022 Annual Teaching Course, planned for September 2022 in Boston, USA, should be conducted in-person and preparations thus continued accordingly. This was the first annual course to be conducted in the USA and it represented an opportunity to spread awareness of the Society in north America where engagement with the Society had been at a lower level than Europe. It proved however to be a very challenging environment, both in terms of the cost of engaging services and the interest within that region to return to an in-person conference

The meeting President, Professor Annick Van den Abbeele, secured substantial industry support and a significant number of companies participated, all providing excellent feedback to their experience of exhibiting despite the disappointing number of registered delegates. It is hoped that these companies will be keen to support future courses and longer term relationships can be established.

The ICISi pancreatic course planned for online delivery in November 2022 was postponed due to insufficient registrations and re-scheduled for March 2023. However, a new edition of the very successful ICISi masterclass on whole-body MRI was developed for classroom delivery in December 2022. Due to demand, the course was repeated on a second day, with excellent feedback received from all who participated.

A re-branded version of the 'Read with the Experts' series, first trialled in October 2021, was launched in February 2023. A series of six segments throughout 2023 will be conducted on hepatobiliary imaging, each curated by an ICIS Fellow. This series will be delivered through the CMRAD platform, with each segment, comprising five cases and associated MCQs. Registrants will have access to review the cases and submit answers to the MCQs. A webinar will be conducted subsequently, hosted by the respective Fellow, at which the diagnosis and correct answer to each case will be revealed. Registration is free to ICIS members; £20 per segment for non-members. This has been marketed as a quiz; at the end of the series, a prize will be awarded for the registrant who has achieved the highest score overall across all six segments. It is hoped that this novel format for learning will encourage increased engagement within the worldwide radiology community and be a source of new Society members as the cost of participating in the overall series is reduced by signing up for membership.

The opportunity to attend the Radiological Society of North America 2022 Annual Scientific Meeting (RSNA) with a complimentary Society booth, was again granted by the Board of RSNA following review of the Society's educational mission. RSNA is the world's largest radiological conference and this presented an opportunity to promote the Society, the Society journal 'Cancer Imaging' and the forthcoming annual teaching course ICIS 2023 to be held in London.

ICIS satellite meetings have remained on hold during the period under review; however, an invitation has been received to participate in the Korean Congress of Radiology (KCR), in Seoul, in September 2023. In addition, discussions have taken place with Taiwanese colleagues to participate in the 22nd Asian Oceanian Congress of Radiology (AOCR 2024) in Taiwan in March 2024. The Satellite Committee, now under the Chairmanship of Dr. Beth McCarville, is reviewing possible partnerships with international contacts to restart a programme of collaborations as the satellite activities are considered an important part of the Society's educational output to reach and teach colleagues around the globe.

Opportunities for improving international visibility of the Society are under constant review and ways to market our events worldwide. Social media tools are utilised to disseminate information, alongside mailings, advertising and the monthly e-newsletter. Regular social media activity is maintained through a range of platforms (Twitter, LinkedIn, Facebook, and YouTube) and the ICIS website is regularly updated to provide current and accurate information. Promoting the Society aims to increase membership, attendance at teaching courses and readership of 'Cancer Imaging' with a view to strengthening the Society's profile, its outreach and influence, as well as generating income for the Society. All these channels enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.

'Cancer Imaging' continues to be published by BioMed Central as an online open access journal. Following the decline in submissions experienced in the post-pandemic period, levels returned and exceeded any previous record. Whilst this impacted substantially on the work required by the editors-in-chief and requested of the editorial board, the overall performance of the journal surpassed its own history by achieving an Impact Factor (IF) of 5.605 in June 2023, the highest ever recorded. This ranked 'Cancer Imaging' within the first quartile in Radiology journals at 27/136 and second quartile in Oncology journals at 79/245, producing a 5-year IF of 4.980. Close collaboration between the publishers, Editors-in-Chief and the editorial team has stimulated this success and contributed to the journal's further growth and development. The number of articles accessed continued to increase throughout the year demonstrating the ongoing interest in the journal.

Professor Rodney Hicks of St Vincent's Hospital, Melbourne, Australia, and Professor Annick Van den Abbeele from the Dana Farber Cancer Institute, Boston, USA, are Joint Honorary Editors-in-Chief, with Professor Stefan Diederich from the Marien Hospital Düsseldorf, Germany, as Deputy Editor. The Editorial Board works to develop the pool of submission reviewers able to take on this important work in a timely manner, whilst supporting the Editors-in-Chief with plans to develop 'Cancer Imaging' further.

Society membership levels are monitored regularly and remain lower since the onset of the pandemic. Numbers are generally boosted through registration to the annual teaching course and the knock-on effect of cancelling the 2020 annual course, the purely online delivery of the 2021 course, and lower registrations achieved for the 2022 annual course has reduced the number of people choosing to renew or take up membership of the Society.

At 28 February 2023, the number of Society members was 142 representing 35 countries worldwide; the number of Fellows was 86 and one Associate Fellow, representing 21 countries.

Structure, Governance and Management

The International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity, governed by its memorandum and articles of association.

The Society is governed by a Board of trustees that oversees the management of the activities which the charity runs. The charity trustees are also Directors of the Company limited by guarantee. Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow. Benefits of membership include reduced registration fees for Society teaching courses, access to the members' area of the website with its expanding repository of recorded lectures and scientific posters and a 20% discount on the article processing charge for accepted publications in Cancer Imaging.

During the period under review the Trustees convened on two occasions, in March 2022 online by virtual means due to the ongoing pandemic, and in a hybrid format in September 2022, on the day before the commencement of the annual teaching course.

Day to decision and activities of the Society are delegated by the trustees to the Executive Board

The Chair of the Executive Board reported to both Trustees' meetings, outlining the Board's ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. Meetings of the Executive Board were held in April, July and November 2022, and January 2023. These meetings were all conducted virtually enabling online participation of the internationally based Board members.

The Executive Board considers it judicious to maintain review of Society policies to ensure robust governance. The risk register is reviewed before each meeting to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk.

The activity implemented by the three sub-committees set up to oversee the ICIS Interactive programme, e-learning, and social media and communications is reviewed at each Executive Board meeting, ensuring a focus on opportunities to develop key elements of Society activity. Consideration is also given to the benefits of Society membership with the intention of retaining existing and attracting new members.

Compliance with the General Data Protection Regulations (GDPR) is maintained in line with the UK General Data Protection Regulation (UK GDPR 2021), tailored by the Data Protection Act 2018, and subject to monitoring by the Society registration with the Information Commissioner's Office.

Risks

The introduction of the risk register has enabled regular review by the Executive Board of any potential risk the Society may face, with any such risks reported to the Trustees. Establishing ways to generate additional income streams and promoting the Society worldwide remain a top priority. Proposed developments will be reviewed to ensure that the perceived benefits would outweigh the possible risk to the Society, which needs to maintain a viable, modern, robust structure from which to operate and develop bearing in mind any financial implications or impact on Society reserves.

The continued global interest in online educational activity in a very competitive virtual environment poses a new challenge and risk to the Society. Having migrated a portion of activity to online delivery, it is important to maintain the Society's reputation as a provider of high-quality education on oncological imaging, with articles published in 'Cancer Imaging' supporting retention of the journal's international standing amongst other journals providing sound research articles and reviews. Enhancing the value of ICIS membership will mitigate the risk of lower member numbers, whose support is an integral element of the Society's continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series.

The financial implications to the Society of any future satellite meetings will be carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of 'Cancer Imaging' will be kept under regular review.

The Trustees also take into consideration potential disasters such as floods, fires, earthquakes, volcanoes, international instability and terrorism that could affect plans for Society teaching courses, particularly those planned as in-person events. The risk posed by infectious diseases remains under review in the light of any potential international instabilities posed by variants of the COVID-19 pandemic. Close monitoring will be maintained to ensure any perceived risk to the Society is assessed in detail and precautions taken as necessary. The Executive Board will continue to keep all these risks under review and report to the Trustees. The city and venue for the Annual Teaching Course is chosen carefully and where possible, a break clause is included in the venue contract to mitigate potential risks. Insurance is reviewed every year.

Reference and administrative details

The Secretariat comprises two part-time employees, supported by contractors, who together maintain full and proper administrative control of all Society activities.

Engagement of personnel continues with two-yearly renewable contracts to allow for appropriate review, including salaries. ICIS does not have a central office facility for personnel, thus overhead running costs are reduced; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters.

During the period under review, significant additional pressure was placed on the Secretariat team by the sudden unexpected loss of the web manager, a key member of the administrative team. A web management company, Blue Flamingo Solutions, has been contracted to undertake management of the website and Society administrative system, covering a proportion of the duties previously undertaken by the Society web manager. Recruitment of an additional part-time member to the Secretariat team is underway to ease the burden of the additional workload placed on the existing personnel.

The Secretariat remain committed to enhancing engagement within the international radiology community to raise the profile of the Society and encourage registration for teaching courses, to deliver successful courses and secure income for the Society.

Financial Review

The Trustees and the Executive Board continue to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. In the post-pandemic world, a shift of delegate preference has emerged which appears to have reduced the appetite for attending in-person conferences and a desire for online education. This shift may pose additional challenge when planning future teaching courses and securing commercial sponsorship for the Society overall and individual teaching courses, taking into account potential lower numbers of registrants.

The Society's corporate sponsorship package aims to secure notable financial commitment to the Society by industry leaders. These sponsorship agreements facilitate robust financial planning and forecasting, are re-negotiated for each contract term, although a level of adverse impact has been demonstrated since the pandemic and ongoing worldwide economic pressures.

Siemens Healthineers, a machine manufacturing company, have continued their support but at the slightly reduced level for this current period. Guerbet, a contrast media company, are renewing their agreement, potentially at an increased level for the forthcoming period.

The option of delivering ICIS Interactive Masterclass series online remains a valued source of income as preference is expressed by delegates for this format.

Substantial industry support was secured by the ICIS 2022 President which helped to defray the unexpectedly high costs associated with the ICIS 2022 meeting, and reduce the financial impact of lower delegate registrations. Following the 2022 annual teaching course, the recorded content was made available for purchase as a package of online content, with access available online until 1 September 2023. This is a new model and to date has generated a modest level of income which will offset some of the costs of providing content in this format. This will be reviewed for future course content.

'Cancer Imaging' remains a significant element of the Society's overall success. Royalty payments based on revenue from published articles and an incentive bonus payment dependent on achievement of pre-determined targets have both provided a beneficial income stream for the Society.

The publishers conduct an annual review of the Article Processing Charges (APC) and whilst the option to apply a surcharge to the APC remains, the proceeds of which would provide direct additional income for the Society from each article published, it is important to remain mindful of the potential impact this could have to limit the journal's attractiveness to authors or reduce the number of submissions.

Global economic challenges, in the wake of the extended pandemic, apparent hesitation to register for in-person courses, accompanied by reluctance to commit to travel, the increased costs associated with travel and hotels, have all contributed to a challenging financial period for the Society. The Trustees therefore have to report a deficit in Society reserves to the year ending 28 February 2023, despite the stringent approach to control of Society expenditure.

The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation to assure a long-term future for the Society, and remain optimistic that a return to pre-pandemic behavior towards conference attendance and travel will emerge as confidence is restored.

Reserves Policy

The Society's policy is to strive to build and hold reserves sufficient to confidently plan to run at least two future annual teaching courses, our flagship event and significant income stream, and be able to provide cover for one failed teaching course. The Society had reserves of £319,414 that were not invested in fixed assets at the year end to February 2023; (2022: £357,740).

Plans for the future

On behalf of the Trustees, the Executive Board and sub-committees work to improve and expand the educational portfolio of the Society, reaching additional colleagues in the radiology community internationally and ensuring a stable financial future to permit further growth and development. The annual teaching course and the ICIS Interactive Masterclass workshop series are two key components to this strategy, in addition to attracting high levels of sponsorship, to generate sufficient income to offset the costs of the administrative structure and add to reserves. The pandemic has necessitated additional focus on careful review of future Society activity.

Whilst there has been some global shift to virtual meetings, online fatigue has encouraged a return to in-person meetings, with the associated networking opportunities. The Executive Board has considered the balance of virtual against in-person meetings and decided that in-person meetings will be reinstated as an integral part of Society activities in 2023.

The third ICIS in Focus meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging will be held in Lisbon in June 2023, supported by the Champalimaud Foundation. The level of financial support previously provided in 2019 will not be available due to the impact of the pandemic on Foundation reserves; however, industry sponsorship is being sought to offset costs of the meeting and to generate a surplus.

The 2023 annual teaching course will be delivered in-person at the British Museum in London, 25-27 September 2023, re-arranged following cancellation of the 2020 annual teaching course and utilising the deposit initially paid for that reservation. It is hoped that returning to same venue in London as the extremely successful 2015 annual course will prove to be financially beneficial. The theme of the meeting will be 'Cancer Imaging: Current guidelines for best practice' with the aim of providing valuable updates for the international radiological and nuclear medicine communities over the course of the three-day meeting, alongside the latest research and developments in the specialist field of cancer imaging.

In view of the costs associated with provision of hybrid delivery, ICIS 2023 will be planned purely as an in-person meeting with the intention of attracting national and international colleagues to re-engage in the iconic setting of the British Museum. The meeting President has secured industry support for the meeting in addition to Society corporate sponsorship; together with registration fee income, this financial support is expected to provide a sound basis from which to deliver a successful event with positive financial outcome.

The President for the annual teaching course in 2024 is based in Singapore. Whilst previous satellite activities have introduced the Society to the Asian market, and recent invitations to participate in the KCR 2024 and AOCR 2024 conferences offer this opportunity, an annual teaching course has never been held in this geographical region. The Singapore Radiological Society (SRS) traditionally conduct their annual course in August, and to avoid direct competition, a collaboration to conduct a joint meeting with the SRS is being explored. This will enable a larger more diverse programme and mitigate some of the anticipated risk of a new, previously untested market for ICIS. In advance of the 2024 annual teaching course, it is hoped to deliver at least one online ICIS Interactive Masterclass to promote the Society and generate interest in the annual course.

Two new ICIS Interactive Masterclass workshops have been developed to expand the portfolio of topics. The workshop on head and neck tumours previously planned for launch in February has been postponed to April 2023. In addition, a new workshop on renal/adrenal tumours is planned for May 2023. Initial delivery is planned as a classroom course, with a view to migrating online in the future.

Further plans to revise the ICIS Interactive thoracic course are on hold pending publication of updated staging guidelines with a view to including the latest information in the updated content.

A new opportunity is being pursued whereby the ICIS Interactive Masterclass in whole-body MRI will be delivered in a hybrid format. This is being conducted in collaboration with the South African Congress of Oncology, to be held in September 2023; one ICIS faculty member will be onsite in Cape Town and the other ICIS faculty will join to teach via Zoom. Delegates will have their own workstation for individual case review throughout the course, with the usual workbook provided. Cases will be hosted on the CMRAD platform and access will be enabled for participants during the course. If this model is successful, the learning experience is considered acceptable and positive feedback is received, it is likely to be considered for future occasions and will open the opportunity to engage with other international societies to offer this delivery format for any masterclass in the portfolio.

The new relationship with Collective Minds Radiology has translated into an annual contract which provides the opportunity for delivery of a number of ICIS Interactive Masterclasses throughout the year at an established fee and without the risk of increased charges, as had been the case with the London venue previously used. This should facilitate a more accurate projection of the financial outcome of the ICIS Interactive series and keep preparation costs at a reduced level.

Following the loss of the web manager, it has become apparent that the technology behind the Society website and administrative system is outdated. A review of the whole system is currently underway, with input from the newly appointed web management team, Blue Flamingo Solutions; it is anticipated that a new website and administrative system should be developed over the coming year.

Establishing an e-learning platform for the Society has been postponed as other activity has precluded the opportunity to develop appropriate content into self-directed e-learning modules on a suitable online platform. Material from retired first edition ICIS Interactive Masterclass courses may be adapted to create modules for independent learning. A charge would be levied for each module, thereby generating an additional income stream for the Society.

The opportunity to re-introduce in-person satellite meetings will be kept under review taking into account the international travel and ensuring those who represent the Society are not exposed to any unnecessary risk. These meetings do present an opportunity to enhance the international profile of the Society, and enable radiologists in locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows; this however has to be balanced against the other logistical factors. The possibility of linking virtually with previous satellite partners may be explored, but potential online fatigue versus the value of in-person meetings will be factored into any decision.

A financial appraisal of any proposed satellite venue is reported to the Trustees to ensure no financial risk is posed to the Society. The Society does not cover any of the speaker expenses; these costs must be met by the host societies or personally.

Marketing Society activities and 'Cancer Imaging' will remain a priority; electronic means and social media enable enhanced communication with members and the wider international community with an interest in oncological imaging. Developing further membership benefits will be reviewed to maintain and increase membership numbers, and assessment of options presented by online education to assist in promoting the Society and enhancing the appeal of membership. Google analytics of traffic to the ICIS website permits review of activity and the number of members will continue to be monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion.

By order of the Board on 24 September 2023



Trevor Pereira
Secretary

INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF
INTERNATIONAL CANCER IMAGING SOCIETY

I report to the charity trustees on my examination of the accounts of the Company for the year ended 28th February 2023 set out on pages 12 to 17.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charites Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102)

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Paul Newton FCA
Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Date: 2 October 2023

INTERNATIONAL CANCER IMAGING SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account)
FOR THE YEAR ENDED 28TH FEBRUARY 2023

	Note	Unrestricted 2023 £	Unrestricted 2022 £
Income from			
Charitable activities			
Conference sponsorship and funding		202,957	102,489
Revenue from conference delegates		43,341	45,054
Membership income		21,299	17,317
ICIS Interactives		35,266	34,102
Journal income		16,575	13,423
Interest receivable		1,967	447
Total income		321,405	212,832
Expenditure on			
Charitable activities			
Conference costs		190,472	20,239
Design, production and advertising		7,421	3,233
Administration			
- Data Manager		4,120	9,557
- Events & Marketing, and General Manager	6	72,560	70,214
- Secretarial Services		8,972	-
- Other		2,500	2,500
Pension Scheme		335	310
Travel and accommodation		15,806	4,793
Printing		6,377	6,919
Bank charges and credit card charges		2,601	2,106
Gifts and donations		100	174
Insurance		1,773	1,111
Accreditations		435	761
Utilities		226	-
Postage/delivery charges		529	1,251
Telephone		577	115
Depreciation		202	270
Software expenses		1,805	1,863
IT support		12,033	-
Miscellaneous		835	561
Rent		977	2,114
Licenses and Permits		553	95
Subscriptions		13	13
Accounting		38,918	34,436
Professional Fees		2,124	-
Consultancy Fee		300	-
Governance cost: Independent Examiners fees		2,079	2,079
Foreign exchange losses/(gains)		(14,104)	9,116
Total expenditure		360,539	173,830
Net (expenditure)/income and movement in funds		(39,134)	39,002
Reconciliation of funds			
Unrestricted fund balance brought forward		358,548	319,546
Unrestricted fund balance carried forward		319,414	358,548

The notes on pages 14 to 17 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

BALANCE SHEET
AS AT 28TH FEBRUARY 2023

	Note	2023 £	2023 £	2022 £	2022 £
Fixed assets					
Tangible fixed assets	2		606		808
Current assets					
Debtors	3	37,506		162,748	
Cash at bank and in hand		308,446		358,396	
		345,952		521,144	
Creditors: Amounts falling due within one year	4	27,144		163,404	
Net current assets			318,808		357,740
Total Net assets less current liabilities			319,414		358,548
Unrestricted Funds	5		319,414		358,548

These accounts have been prepared in accordance with the provisions available to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

For the financial year ended 28 February 2023 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements were approved by the Board on 24 September 2023 and signed on their behalf by:

Prof. Anwar Padhani
Trustee

Prof. Dow Mu Koh
Trustee

Company Registration number: 03908709

The notes on pages 14 to 17 form part of these financial statements.

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guaranteed registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

(b) Going concern

There are no significant uncertainties about the charity's ability to continue as a going concern.

(c) Income recognition

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

(d) Expenditure recognition

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

(e) Irrecoverable VAT

Irrecoverable VAT is included with the expense upon which it is incurred.

(f) Transactions in foreign currencies

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

(g) Tangible fixed assets

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)

1 ACCOUNTING POLICIES (CONTINUED)

(h) Cash at bank and in hand
Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

(i) Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation arising from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are recognised at their settlement amount

(j) Financial instruments
The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 TANGIBLE FIXED ASSETS

	Computer equipment	*Total*
	£	£
Cost		
As at 1st March 2022	1,150	1,150
Additions	-	-
Disposals	-	-
As at 28th February 2023	1,150	1,150
Depreciation		
As at 1st March 2022	342	342
Charge for year	202	202
Disposals	-	-
As at 28th February 2023	544	544
Net book value		
As at 28th February 2023	606	606
As at 29th February 2022	808	808

3 DEBTORS

	2023	*2022*
	£	£
Trade debtors	22,820	149,658
Prepayments and accrued income	14,686	13,090
	37,506	162,748

4 CREDITORS

	2023 £	2022 £
Trade creditors	1,899	765
Accruals and deferred income	25,245	162,639
	27,144	163,404

5 MOVEMENT ON FUNDS

	At 1st March 2022 £	Total Income £	Total Expenditure £	At 28th February 2023 £
Unrestricted Funds				
General Fund	358,548	321,405	(360,539)	319,414

	At 1st March 2021 £	Total Income £	Total Expenditure £	At 29th February 2022 £
Unrestricted Funds				
General Fund	319,546	212,832	(173,830)	358,548

6 STAFF COSTS

	2023 £	2022 £
Salaries	68,585	65,949
Pension	1,667	1,604
Social security	2,308	2,661
	72,560	70,214
Average no. staff	2	2

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £49,505 (2022: £46,014). There were no other related party transactions in the year.

7 TRUSTEES' REMUNERATION

None of the trustees received any remuneration from the charity during the year (2022: none). Expenses incurred on behalf of the Society and reimbursed to trustees during the year to 28th February 2023 amounted to £nil (2022: £nil).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

8 LIMITED BY GUARANTEE

The company is limited by guarantee, each member (termed "Fellow" from October 2004) having guaranteed to pay £1 should the company be wound up.

INTERNATIONAL CANCER IMAGING SOCIETY

England & Wales - Charity number 1082082

Accounts

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

28TH FEBRUARY 2022

Charity number 1082082
Company number 03908709

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

28TH FEBRUARY 2022

Contents **Page**

Report of the Trustees	1-9
Independent Examiner's Report	10
Statement of Financial Activities	11
Balance Sheet	12
Notes to the Accounts	13-16

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 28TH FEBRUARY 2022

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 28th February 2022.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband
Prof. Rodney Reznek
Dr. Conor Collins
Dr. Leslie Quint (resigned 1 November 2021)
Prof. Stefan Diederich
Prof. Anwar Padhani
Prof. Harriet Thoeny
Prof. Dow-Mu Koh
Prof. Andrea Rockall
Dr. Beth McCarville
Dr. Evis Sala
Prof. Willem Oyen
Dr. Rosemarie Forstner
Dr. Giovanni Morana
Dr. Aslam Sohaib
Prof. Rodney Hicks
Prof. Annick Van Den Abbeele
Prof. Olivier Lucidarme
Dr. Thierry Huisman (appointed 1 November 2021)
Prof. Pek Lan Khong (appointed 1 November 2021)
Prof. Giuseppe Petralia (appointed 1 November 2021)

The key management personnel are the trustees and Maureen Watts - General Manager.

Secretary and Registered Office
Mr Trevor Pereira
41 Waddington Way
London
SE19 3UB

Bankers
Barclays Bank plc
9 Portman Square
London
W1A 3AL

Independent Examiners
Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Solicitors
Radcliffes Le Brasseur
5 Great College Street
Westminster
London
SW1P 3SJ

Objects and Activities to achieve a public benefit

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

a) The integration of cross sectional imaging techniques, including computed tomography, magnetic resonance imaging, ultrasonography and nuclear medicine techniques, conventional radiology and developing new imaging modalities
b) The study and analysis of the efficacy and outcome of diagnostic imaging studies
c) The promotion of interest in oncology and the facilitation of exchange of ideas by the organisation of scientific meetings, multicentre research studies, seminars and conferences on oncological imaging
d) The provision of postgraduate courses in oncological imaging

The main activities undertaken by the Society to meet these objects is through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

Structure, Governance and Management

International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity and is governed by its memorandum and articles of association.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow.

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

Achievements and Performance

During the period under review the Trustees convened on two occasions, in March 2021 and in September 2021 for the Annual General Meeting. Both meetings were conducted online by virtual means due to the ongoing pandemic continuing to preclude travel and face to face meetings.

The Chair of the Executive Board reported to both Trustees' meetings, outlining the Board's ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. Meetings of the Executive Board were held in April, July, September and November 2021, and January 2022. These meetings were all conducted virtually enabling online participation of the internationally based Board members. The Secretariat comprises two part-time employees and two contracted staff who together maintain full and proper administrative control of all Society activities, to ensure the Society is running smoothly.

The Executive Board considers it judicious to maintain review of Society policies to ensure robust governance. The risk register introduced in 2020 is reviewed before each meeting to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk. A suite of Human Resources policies has been developed with input from an HR Consultant. The Terms of Reference of the Executive Board were reviewed to ensure these remain fit for purpose. Updates were agreed at the Trustees' AGM, in particular that four members may be elected to the Board (rather than three) and that at least five meetings per year should be held, rather than six, now that the Executive Board has been established for over 10 years.

The Chairmen of the three sub-committees set up to oversee the ICIS Interactive programme, e-learning, and social media and communications report to each Executive Board meeting, providing the opportunity for regular review, to focus attention and encourage growth for key elements of Society activity.

Following cancellation of the annual teaching course in September 2020, it had been hoped to resume in-person meetings from 2021 but it remained evident that both the physical and financial risks would be too high. In March 2021 the Trustees agreed that all meetings should continue to be arranged as virtual meetings. This included the AI & Machine Learning course scheduled for May 2021, planned for Lisbon, Portugal, and the Annual Teaching Course in London deferred from 2020 to September 2021. In addition, it was agreed that all ICIS Interactive Masterclass workshops would be conducted online until confidence of being in a classroom setting had returned.

In the virtual setting, registrations for both the AI & Machine Learning course in May 2021 and the annual teaching course in September 2021 proved lower than anticipated, highlighting the level of competition from other organisations who had also migrated to online meetings in view of the pandemic, thereby creating a rather saturated market.

The ICIS Interactive Masterclass workshops however remained a very popular element of the Society's educational offering, and adoption of the online format for these courses proved very popular and successful. Five days' online masterclass workshops were held in 2021, maintaining a valuable income stream for the Society.

During the Annual General Meeting in September 2021, the Trustees undertook a further review of the consequences of the pandemic and whilst a degree of uncertainty remained over the preferred format of teaching courses, it was agreed to plan the ICIS Interactive Imaging of Gynaecological Cancers workshop as a classroom course in January 2022.

By mid-December 2021, however, registrations for this course remained lower than would have been hoped, enquiries continued on the availability of this course online and the decision was taken to postpone the course and conduct it online in spring 2022, to attract a larger number of delegates and be sure of generating a surplus of income.

The series of bi-monthly webinars introduced in October 2020 have continued to generate substantial interest from a worldwide audience. The webinars are free to watch live and subsequently available in the ICIS members' area of the website. A range of topics is covered, often providing the opportunity to promote forthcoming ICIS Interactive workshops or other Society activities.

A further new initiative was undertaken in October 2021, 'Read with the Experts'. Registrants were given the opportunity to review cases in advance of online mentored review in a seminar style setting, with cases available for a further 72 hours after the sessions to allow personal review and reflection. The PACS platform of the corporate sponsor, INFINITT, was utilized and a partnership with Amazon Web Services (AWS) was secured for this event with sponsored provision of "cloud time". Registration was free of charge for participants, and the industry support enabled this event to be cost-neutral for the Society. Unfortunately, interest was very limited with a low number of registrants and post-event analytics demonstrated little uptake of this free facility. A review will be undertaken to assess the value of creating similar content in a renewed format to provide e-learning material for the Society.

A new opportunity was afforded in November 2021 to attend the Radiological Society of North America Annual Scientific Meeting (RSNA) with a complimentary Society booth, granted by the Board of RSNA following review of the Society's educational mission. RSNA is the world's largest radiological conference and this presented an opportunity to promote the Society, the Society journal *'Cancer Imaging'* and the forthcoming annual teaching course ICIS 2022 to be held in Boston.

ICIS satellite meetings have remained on hold during the period under review. Whilst considered an important part of the Society's educational output to reach and teach colleagues around the globe, the ongoing pandemic has necessitated a pause to satellite meeting activity.

Opportunities for improving international visibility of the Society are under constant review and ways to market our events worldwide. Social media tools are utilised to disseminate information, alongside mailings, advertising and the monthly e-newsletter. Regular social media activity is maintained through a range of platforms (Twitter, LinkedIn, Facebook, and YouTube) and the ICIS website is regularly updated to provide current and accurate information. Promoting the Society aims to increase membership, attendance at teaching courses and readership of *'Cancer Imaging'* with a view to strengthening the Society's profile, its outreach and influence, as well as generating income for the Society. All these channels enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.

The Society continues to monitor its compliance with the General Data Protection Regulations (GDPR), through its registration with the Information Commissioner's Office and in line with the UK General Data Protection Regulation (UK GDPR 2021), tailored by the Data Protection Act 2018.

'Cancer Imaging' continues to be published by BioMed Central as an online open access journal. The number of submissions fell during the period under review, similar to the decrease experienced by other journals. However, the journal's performance was not affected and in June 2021 the Impact Factor was announced at 3.909, the highest ever recorded in the journal's history. This increased *'Cancer Imaging'*s ranking amongst other Radiology and Oncology journals, and produced a 5-year IF of 3.849. Since securing the new contract with the publishers, close collaboration between the Editors-in-Chief and the editorial team has stimulated the journal's further growth and development.

Professor Rodney Hicks from the Peter MacCallum Cancer Centre, Melbourne, Australia, and Dr Annick Van den Abbeele from the Dana Farber Cancer Institute, Boston, USA, are Joint Honorary Editors-in-Chief, with Professor Stefan Diederich from the Marien Hospital Düsseldorf, Germany, as Deputy Editor. The Editorial Board works to develop the pool of submission reviewers able to take on this important work in a timely manner, whilst supporting the Editors-in-Chief with plans to develop *'Cancer Imaging'* further.

The number of Society members has remained lower since the onset of the pandemic. Numbers are generally boosted through registration to the annual teaching course and the knock-on effect of cancelling the 2020 annual course and the purely online delivery of the 2021 course, has reduced the number of people deciding to renew or take up membership of the Society.

One of the key membership benefits is reduced registration fees for Society teaching courses; other benefits include a 20% discount on the article processing charge for accepted publications in Cancer Imaging, and access to the members' area of the website with its expanding repository of recorded lectures and scientific posters. The Executive Board continues to review other possible elements to promote and enhance the appeal of joining the Society.

At 28 February 2022, the number of Society members was 146 representing 35 countries worldwide; the number of Fellows was 76 and one Associate Fellow, representing 19 countries.

Financial Review

The Trustees and the Executive Board continue to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. The ongoing impact of the pandemic cannot be underestimated. Following cancellation of the 2020 annual teaching course, migration of the 2021 annual teaching course to a fully virtual meeting resulted in a significantly reduced income for two successive years. The Trustees are conscious that the duration of the pandemic will prolong economic constraints and present an additional challenge when securing commercial sponsorship of future annual teaching courses, also potentially affecting the number of delegates registering.

Migration of the ICIS Interactive Masterclass series to an online setting proved a valuable source of income without which the burden placed on Society reserves would have been significantly higher. During the period under review, five online workshops were delivered, generating valuable income during this challenging time. In view of the excellent feedback to the online format, it is anticipated that online delivery of some courses will continue in the future, alongside a programme of classroom courses provided pandemic restrictions permit in-person attendance.

The webinar series has attracted attention from a widespread geographical audience and also some industry interest with sponsorship received from companies working within the webinar subject field. This support has proved very valuable to defray Society running expenses.

Engagement of personnel continues with two-yearly renewable contracts to allow for appropriate review, including salaries. ICIS does not have a central office facility for personnel, thus overhead running costs are reduced; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters. Engagement within the international radiology community is under constant review and registration for teaching courses is closely monitored, securing income for the Society.

The Society's corporate sponsorship package is aimed at large companies who are willing to make a notable financial commitment to the Society. These sponsorship agreements facilitate robust financial planning and forecasting, are re-negotiated for each contract term, but have been adversely affected by the pandemic due to worldwide economic pressures.

Siemens Healthineers, a machine manufacturing company, have continued their support but at the slightly reduced level for this current period. Guerbet, a contrast media company, renewed their support, also at a lower level than in previous periods.

A new corporate sponsor, INFINITT, a South Korean PACS company, provided sponsorship for the 15-month period to December 2021, but declined to continue their support in 2022. It may be reconsidered in the future but was not deemed to fit within the company's current plan.

'*Cancer Imaging*' is a significant element of the Society's overall success. Royalty payments based on revenue from published articles and an incentive bonus payment dependent on achievement of pre-determined targets have both proved a valuable additional income stream for the Society.

The option to apply a surcharge to the Article Processing Charges (APC) remains, the proceeds of which would provide direct additional income for the Society from each article published. However, it is important to be mindful of the potential impact this could have to limit the journal's attractiveness to authors or further reduce the number of submissions.

The Trustees are pleased to report that the overall outcome to the year ending 28 February 2022 shows an increase of Society reserves, placing the Society in a strengthened financial position despite the challenges faced during this financial period, and the substantial impact of the pandemic on the Society. This achievement has been possible due to the support secured from industry and income generated by online delivery of ICISi masterclass workshops, alongside the stringent approach to control of Society expenditure.

The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation to assure a long-term future for the Society.

Reserves Policy

The Society's policy is to strive to build and hold reserves sufficient to confidently plan to run at least two future annual teaching courses, our flagship event and significant income stream, and be able to provide cover for one failed teaching course. The Society had reserves of £357,740 that were not invested in fixed assets at the year end to February 2022; (2021: £318,468).

Plans for the future

On behalf of the Trustees, the Executive Board and sub-committees constantly strive to improve and expand the educational portfolio of the Society, reaching additional colleagues in the radiology community internationally and ensuring a stable financial future to permit further growth and development. The annual teaching course and the ICIS Interactive Masterclass workshop series are two key components to this strategy, in addition to attracting high levels of sponsorship, to generate sufficient income to offset the costs of the administrative structure and add to reserves. The pandemic has necessitated additional focus on careful review of future Society activity.

Whilst during 2021 there was a global shift to virtual meetings, an element of online fatigue has become apparent and a degree of desire for in-person meetings with networking opportunities has returned. The Executive Board has considered the balance of virtual against in-person meetings and decided that in-person meetings should be included in Society activities in 2022.

Discussions are underway with the Champalimaud Foundation to review the possibility of holding the third *ICIS in Focus* meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging in June 2022. The previous financial support provided by the Foundation will not be available due to the impact of the pandemic on Foundation reserves, but alternative funding arrangements are being considered.

The 2022 annual teaching course will be delivered in-person in Boston, Massachusetts, USA, 12-14 September 2022, the first annual course to be held outside the UK or Europe. It is hoped this will promote the Society, generate more interest and expand the membership in the USA. The theme of the meeting has been chosen as 'Cancer Imaging: An All-Inclusive Specialty' with the aim of engaging the radiological and nuclear medicine communities globally with coverage and input from all continents of the world over the course of the three-day meeting.

Consideration will be given in due course whether to include any hybrid element to this meeting but it is hoped that the opportunity to resume in-person meetings and networking with international colleagues will result in positive registrations. The meeting President has secured substantial industry support for the meeting which should provide a sound basis from which to deliver a financially successful event.

The President for the annual teaching course in 2023 is based in Paris, France. However, the intention is to hold this annual teaching course in London, utilising the deposit carried over at the British Museum from the cancellation of ICIS 2020. The Trustees are grateful to the British Museum administrators who have been very supportive in permitting this prolonged delay of three years.

Two new ICIS Interactive Masterclass workshops are being developed to expand the portfolio of topics covered. In February 2023 the workshop on head and neck tumours will be launched, with a new workshop on renal/adrenal tumours planned for later in 2023. For the initial delivery, these will be classroom courses, with the possibility to migrate online in the future.

Further plans include revision of the thoracic course, last held in 2018, and development of a second edition of the ever-popular whole-body MRI course. The possibility of a third edition prostate course or conducting the existing prostate course in Sweden is also under review.

Establishing an e-learning platform remains under review with the proposal to introduce self-directed e-learning modules. Material from retired first edition ICIS Interactive Masterclass courses will be adapted to create modules for independent learning. A charge will be levied for each module, thereby generating an additional income stream for the Society.

The opportunity to resume in-person satellite meetings will be kept under review taking into account the feasibility of international travel and ensuring those who represent the Society are not exposed to any unnecessary risk. These meetings do present an opportunity to enhance the international profile of the Society, and enable radiologists in locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows, but this has to be balanced against the other logistical factors. The possibility of linking virtually with previous satellite partners may be explored, but potential online fatigue versus the value of in-person meetings will be factored into any decision.

A financial appraisal of any proposed satellite venue is reported to the Trustees to ensure no financial risk is posed to the Society. The Society does not cover any of the speaker expenses; these costs must be met by the host societies or personally.

Marketing Society activities and *'Cancer Imaging'* remain a priority; electronic means and social media are used to enhance communication with members and the wider international community with an interest in oncological imaging. Developing further membership benefits will be important to maintain and increase membership numbers, and assessment of options presented by the shift to online education. Google analytics of traffic to the ICIS website permits review of activity and the number of members is monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion.

Risks

The introduction of the risk register has enabled regular review by the Executive Board of any potential risk the Society may face, with any such risks reported to the Trustees. Establishing ways to generate additional income streams and promoting the Society worldwide remain a top priority. Proposed developments will be reviewed to ensure that the perceived benefits would outweigh the possible risk to the Society, which needs to maintain a viable, modern, robust structure from which to operate and develop bearing in mind any financial implications or impact on Society reserves.

The sudden global increase of online educational activity in a very competitive virtual environment poses a new challenge and risk to the Society. Whilst migrating activity to online delivery, it is important that the Society's reputation is maintained as a provider of high-quality education on oncological imaging, with articles published in *'Cancer Imaging'* supporting retention of the journal's international standing amongst other journals providing sound research articles and reviews. Enhancing the value of ICIS membership will mitigate the risk of lower member numbers, whose support is an integral element of the Society's continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series. The financial implications to the Society of any proposed Satellite meetings are carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of Cancer Imaging will be kept under regular review.

The Trustees also take into consideration potential disasters such as floods, fires, earthquakes, volcanoes, international instability and terrorism that could affect plans for Society teaching courses, particularly those planned as in-person events. The risk posed by infectious diseases remains under stringent review in the light of ongoing international instabilities posed by the COVID-19 pandemic. This will be monitored closely to ensure any potential risk to the Society is assessed in detail and precautions taken as necessary. The Executive Board will continue to keep all these risks under review and report to the Trustees. The city and venue for the Annual Teaching Course is chosen carefully and where possible, a break clause is included in the venue contract to mitigate these potential risks. Insurance is reviewed every year.

By order of the Board on 11 September 2022



Trevor Pereira
Secretary

INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF
INTERNATIONAL CANCER IMAGING SOCIETY

I report to the charity trustees on my examination of the accounts of the Company for the year ended 28th February 2022 set out on pages 11 to 16.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charites Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102)

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Paul Newton FCA
Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Date: 21 September 2022

INTERNATIONAL CANCER IMAGING SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account)
FOR THE YEAR ENDED 28TH FEBRUARY 2022

	Note	*Unrestricted 2022* £	*Unrestricted 2021* £
Income from			
Charitable activities			
Conference sponsorship and funding		102,489	37,848
Revenue from conference delegates		45,054	-
Membership income		17,317	20,686
ICIS Interactives		34,102	36,674
Journal income		13,423	17,039
Other income		-	397
Interest receivable		447	2,825
Total income		212,832	115,469
Expenditure on			
Charitable activities			
Conference costs		20,239	5,868
Design, production and advertising		3,233	1,051
Administration			
- Data Manager		9,557	13,018
- Events & Marketing, and General Manager	6	70,214	67,829
- Other		2,500	70
Pension Scheme		310	310
Travel and accommodation		4,793	104
Printing		6,919	4,760
Bank charges and credit card charges		2,106	997
Gifts and donations		174	-
Insurance		1,111	-
Accreditations		761	-
Postage/delivery charges		1,251	462
Telephone		115	65
Depreciation		270	306
Software expenses		1,863	921
IT support		-	1,250
Rent		2,114	988
Miscellaneous		561	701
Licenses and Permits		95	137
Books and Publications		-	26
Subscriptions		13	13
Accounting		34,436	33,997
Consultancy Fee		-	5,186
Governance cost: Independent Examiners fees		2,079	1,968
Foreign exchange losses/(gains)		9,116	(876)
Total expenditure		173,830	139,151
Net income / movement in funds		39,002	(23,682)
Reconciliation of funds			
Unrestricted fund balance brought forward		319,546	343,228
Unrestricted fund balance carried forward		358,548	319,546

The notes on pages 13 to 16 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

BALANCE SHEET
AS AT 28TH FEBRUARY 2022

	Note	2022 £	2022 £	2021 £	2021 £
Fixed assets					
Tangible fixed assets	2		808		1,078
Current assets					
Debtors	3	162,748		17,836	
Cash at bank and in hand		358,396		366,269	
		521,144		384,105	
Creditors: Amounts falling due within one year	4	163,404		65,637	
Net current assets			357,740		318,468
Total Net assets less current liabilities			358,548		319,546
Unrestricted Funds	5		358,548		319,546

These accounts have been prepared in accordance with the provisions available to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

For the financial year ended 28 February 2022 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements were approved by the Board on 11 September 2022 and signed on their behalf by:

Prof. Anwar Padhani
Trustee

Prof. Dow Mu Koh
Trustee

Company Registration number: 03908709

The notes on pages 13 to 16 form part of these financial statements.

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guaranteed registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

(b) Going concern

There are no significant uncertainties about the charity's ability to continue as a going concern.

(c) Income recognition

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

(d) Expenditure recognition

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

(e) Irrecoverable VAT

Irrecoverable VAT is included with the expense upon which it is incurred.

(f) Transactions in foreign currencies

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

(g) Tangible fixed assets

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)

1 ACCOUNTING POLICIES (CONTINUED)

(h) Cash at bank and in hand
Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

(i) Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation arising from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are recognised at their settlement amount

(j) Financial instruments
The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 TANGIBLE FIXED ASSETS

	Computer equipment	*Total*
	£	£
Cost		
As at 1st March 2021	1,150	1,150
Additions	-	-
Disposals	-	-
As at 28th February 2022	1,150	1,150
Depreciation		
As at 1st March 2021	72	72
Charge for year	270	270
Disposals	-	-
As at 28th February 2022	342	342
Net book value		
As at 28th February 2022	808	808
As at 29th February 2021	1,078	1,078

3 DEBTORS

	2022	*2021*
	£	£
Trade debtors	149,658	2,131
Prepayments and accrued income	13,090	15,705
	162,748	17,836

4 CREDITORS

	2022 £	2021 £
Trade creditors	765	283
Accruals and deferred income	162,639	65,354
	163,404	65,637

5 MOVEMENT ON FUNDS

	At 1st March 2021 £	Total Income £	Total Expenditure £	At 28th February 2022 £
Unrestricted Funds				
General Fund	319,546	212,832	(173,830)	358,548

	At 1st March 2020 £	Total Income £	Total Expenditure £	At 29th February 2021 £
Unrestricted Funds				
General Fund	343,228	115,469	(139,151)	319,546

6 STAFF COSTS

	2022 £	2021 £
Salaries	65,949	63,913
Pension	1,604	1,295
Social security	2,661	2,621
	70,214	67,829
Average no. staff	2	2

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £46,014 (2021: £41,198). There were no other related party transactions in the year.

7 TRUSTEES' REMUNERATION

None of the trustees received any remuneration from the charity during the year (2021: none). Expenses incurred on behalf of the Society and reimbursed to trustees during the year to 28th February 2022 amounted to £nil (2021: £nil).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

8 LIMITED BY GUARANTEE

The company is limited by guarantee, each member (termed "Fellow" from October 2004) having guaranteed to pay £1 should the company be wound up.

INTERNATIONAL CANCER IMAGING SOCIETY

England & Wales - Charity number 1082082

Accounts

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

28TH FEBRUARY 2021

Charity number 1082082
Company number 03908709

JCS ACCOUNTANTS

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

28TH FEBRUARY 2021

Contents **Page**

Report of the Trustees	1-9
Independent Examiner's Report	10
Statement of Financial Activities	11
Balance Sheet	12
Notes to the Accounts	13-16

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 28TH FEBRUARY 2021

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 28th February 2021.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband
Prof. Rodney Reznek
Dr. Evis Sala
Dr. Conor Collins
Dr. Leslie Quint
Prof. Stefan Diederich
Prof. Anwar Padhani
Prof. Harriet Thoeny
Prof. Dow-Mu Koh
Prof. Andrea Rockall
Dr. Beth McCarville
Prof. Willem Oyen
Dr. Rosemarie Forstner
Dr. Giovanni Morana
Mr. St John Brown (resigned 17 April 2020)
Dr. Aslam Sohaib
Prof. Rodney Hicks
Prof. Annick Van Den Abbeele
Prof. Olivier Robert Lucidarme (appointed 14 September 2020)
Mr. Andrew Hall (appointed 6 May 2020 and resigned 14 September 2020)

The key management personnel are the trustees and Maureen Watts - General Manager.

Secretary and Registered Office
Mr Trevor Pereira
41 Waddington Way
London
SE19 3UB

Bankers
Barclays Bank plc
9 Portman Square
London
W1A 3AL

Independent Examiners
Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Solicitors
Radcliffes Le Brasseur
5 Great College Street
Westminster
London
SW1P 3SJ

Objects and Activities to achieve a public benefit

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

a) The integration of cross sectional imaging techniques, including computed tomography, magnetic resonance imaging, ultrasonography and nuclear medicine techniques, conventional radiology and developing new imaging modalities
b) The study and analysis of the efficacy and outcome of diagnostic imaging studies
c) The promotion of interest in oncology and the facilitation of exchange of ideas by the organisation of scientific meetings, multicentre research studies, seminars and conferences on oncological imaging
d) The provision of postgraduate courses in oncological imaging

The main activities undertaken by the Society to meet these objects is through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

Structure, Governance and Management

International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity and is governed by its memorandum and articles of association.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow.

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

Achievements and Performance

During the period under review the Trustees convened on two occasions, in March 2020 and in September 2020 for the Annual General Meeting. Both meetings were conducted online by virtual means following the World Health Organisation (WHO) declaration on 30 January 2020 that the COVID-19 outbreak presented a Public Health Emergency of International Concern, and the subsequent categorisation on 11 March 2020 of a pandemic resulting in global enforcement of major restrictions to in-person gatherings or travel.

In March 2020 it was evident that Society activity during the ensuing six months would be adversely affected by the pandemic and an urgent review of planned teaching courses was undertaken. It was agreed that ICIS Interactive Masterclass workshops planned for late spring and summer 2020 should be postponed until spring 2021. A further review in three months was agreed to reconsider whether those planned for after September 2020 would go ahead in late autumn 2020 or be postponed until spring/summer 2021. The decision was taken to defer the annual teaching course planned to be held in London in September 2020 until September 2021. In addition, the AI & Machine Learning meeting scheduled for June 2020 in Lisbon was postponed, with a view to planning this for May 2021.

The Trustees undertook a further review of the consequences of the pandemic at the Annual General Meeting in September 2020. Due to the ongoing concerns surrounding the continued global impact of the pandemic, the Trustees agreed that planned educational activity should continue in a virtual format, with consideration given to conducting the 2021 annual teaching course as a hybrid meeting. Uncertainty remained over the preferred format of the AI meeting, planned for May 2021. It was agreed that the Organising Committee of each meeting would review the circumstances of the pandemic in late 2020 and refer a final decision on the meetings to the Executive Board in early 2021.

The Chair of the Executive Board reported to both Trustees' meetings, outlining the Board's ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. The Secretariat comprises two part-time employees and two contracted staff who together maintain full and proper administrative control of all Society activities, to ensure the Society is running smoothly. Meetings of the Executive Board were held in April, July, September and November 2020, and February 2021. These meetings were all conducted virtually enabling online participation of the internationally based Board members.

Following proposals at the 2019 Society Annual General Meeting, a number of amendments were required to the ICIS Articles of Association. In the course of these amendments, an overall review was undertaken by the Society solicitor to confirm the Articles remain fit for purpose in 2020. In the light of the pandemic, it was considered prudent to permit business meetings to be conducted wholly virtually; in addition, Directors will be permitted to serve a third three-year term, the Editor-in-Chief shall become a Director on appointment, and when engaging the Society Honorary Treasurer with appropriate knowledge and experience for the role, on occasion that he/she is not a Fellow, he/she will not become a Director and payment of an honorarium shall be permitted. Voting at the Annual General Meeting unanimously carried the special resolution for these amendments, and the new Articles of Association were adopted on 14 September 2020.

The ICIS Bye-Laws also underwent review and were adapted to include the agreed provision that PhD is an eligible criteria for election to Fellowship or Associate Fellowship of the Society.

The Executive Board considered it judicious to undertake a review of Society policies to maintain robust governance; this review is ongoing. To date, a risk register has been introduced to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk. As the Society relies on commercial sponsorship to support its educational activities, a sponsorship policy has been developed to clarify the terms governing acceptance of any such sponsorship. In addition, a Conflict of Interests (COI) policy is now in place. All ICIS Fellows will be required to complete a COI declaration with a register of these declarations held by the Society General Manager. Before the commencement of Society meetings, Trustees and Fellows will be asked to declare any COIs with agenda items.

Three new sub-committees have been established, namely ICIS Interactive, e-learning, and social media and communications. The sub-committee chairs report to each Executive Board meeting. These committees provide the opportunity for regular review, to focus attention and encourage growth for key elements of Society activity. Of note, a series of bi-monthly webinars has been introduced, conducted primarily by ICIS Fellows, covering a range of topics. To date this series has been well attended, generating substantial interest from a worldwide audience. The webinars are free to watch live and subsequently available in the ICIS members' area of the website.

Introduction of the webinar series was prompted by the pandemic and the necessity of remaining engaged with our international audience through purely virtual means, in an increasingly competitive arena. The Executive Board was acutely aware of potential loss of the Society's profile due to cancellation of the 2020 annual teaching course, and the need to establish alternative ways for the Society to retain its following and international engagement.

The ICIS Interactive Masterclass workshops remain a very popular element of the Society's educational offering and due to the pandemic, a virtual alternative was urgently explored to try and replicate the classroom format, maintaining Society activity and generating income. A trial hepatobiliary masterclass was planned, utilizing a platform whereby delegates could login to individual workstations remotely whilst interaction between faculty and delegates would be enabled via Zoom. 20 registrations were offered; the course sold out and was well-received, leading to the introduction of a series of virtual ICIS Interactive courses. The masterclass in oncological whole-body MRI was conducted as an online course in late 2020, and the prostate course was held online in February 2021. All courses sold out and generated a waiting list for future courses; 22 delegates participated on each occasion and feedback was extremely positive. Virtual delivery has expanded the reach of these courses, with delegates joining from as far afield as Chile, the West Indies, South Africa and Singapore.

The satellite meetings are considered an important part of the Society's educational output, ensuring that countries and colleagues from around the globe benefit from the expertise of the ICIS Fellows with minimal financial risk to the Society. The ongoing pandemic has necessitated a pause to satellite meeting activity; the possibility of linking virtually with previous satellite partners is being explored and in due course, when international travel is feasible, resumption of in-person satellite meetings will be reviewed.

Social media tools are utilised to disseminate information, alongside the traditional marketing methods of mailings, advertising and newsletters. The Society continues to monitor its compliance with the General Data Protection Regulations (GDPR), through its registration with the Information Commissioner's Office and in line with the UK General Data Protection Regulation (UK GDPR 2021), tailored by the Data Protection Act 2018.

Opportunities for improving international visibility of the Society are under constant review and ways to market our events worldwide. Regular social media activity is maintained through a range of platforms (Twitter, Facebook, LinkedIn and YouTube) and the ICIS website is regularly updated to provide current and accurate information. Promoting the Society aims to increase membership, attendance at teaching courses and readership of the Society's journal (Cancer Imaging), with a view to strengthening the Society's profile, its outreach and influence, as well as generating income for the Society. All these enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.

The Society online journal 'Cancer Imaging' continues to be published by BioMed Central as an online open access journal. A new contract with BioMed Central has been signed covering an eight-year term, January 2020 – December 2027. During the past year, the number of submissions has continued to rise, with the second highest number of published articles recorded in 2020. The journal's Impact Factor showed a reduction in 2020 to 2.193, whilst overall article downloads has continued to increase. Cancer Imaging has retained its positive ranking in the field of Radiology, Nuclear Medicine & Medical Imaging journals. Close collaboration with the publishers to stimulate further growth and development of the journal is key to its success.

Professor Rodney Hicks from the Peter MacCallum Cancer Centre, Melbourne, Australia, and Dr Annick Van Den Abbeele from the Dana Farber Cancer Institute, Boston, USA, are Joint Honorary Editors-in-Chief of 'Cancer Imaging' with Professor Stefan Diederich from the Marien Hospital Düsseldorf, Germany, as Deputy Editor. The editorial board works to develop the pool of submission reviewers able to take on this important work in a timely manner, whilst supporting the Editors-in-Chief with plans to further develop the journal.

A further impact of the pandemic has been recorded by a fall in membership numbers; cancellation of the 2020 annual teaching course adversely affected renewals which would have taken place alongside registration for the annual teaching course as members benefit from reduced registration fees.

The Executive Board continues to review ICIS Membership benefits to provide competitive advantages of being or becoming an ICIS member. In addition to reduced registration fees for ICIS teaching courses, a 20% discount is available on the article processing charge for accepted publications in Cancer Imaging, and the members' area of the website includes an expanding repository of recorded lectures and scientific posters, accessible to members at any time. A refresh of the ICIS website has resulted in a more modern-looking website with enhanced user-friendly functions for members and visitors to the site, and the introduction of a personal dashboard for members, providing individual records of ICIS activity and the ability to directly download CPD certificates, invoices and receipts.

At 28 February 2021, the number of Society members was 137 representing 38 countries worldwide; the number of Fellows was 78 and one Associate Fellow.

Financial Review

The Trustees and the Executive Board continue to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. The impact of the pandemic cannot be underestimated. The sudden changes to Society activity and opportunities for generating income against the ongoing costs of maintaining efficient administration of the Society posed a substantial challenge during this financial period. An overall deficit is to be expected in these exceptional circumstances and the Trustees are very grateful to all those who have contributed to minimising this deficit, through a range of measures, for example, migrating the ICIS Interactive Masterclass workshops to online delivery and introducing the webinar series to maintain the Society's international presence.

Engagement of personnel continues with two-yearly renewable contracts to allow for appropriate review, including salaries. ICIS does not have a central office facility for personnel; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters. Engagement within the international radiology community is under constant review and registration for teaching courses is closely monitored, securing income for the Society.

The Society's corporate sponsorship package is aimed at large companies who are willing to make a notable financial commitment to the Society. These sponsorship agreements facilitate robust financial planning and forecasting, and are re-negotiated for each contract term, but have been adversely affected by the pandemic due to worldwide economic pressures.

Siemens Healthineers, a machine manufacturing company, have continued their support but at a slightly reduced level for this current period. Ongoing discussions are underway with the contrast media company Guerbet, to continue their long-term support of ICIS; news is awaited of the level of support to be provided at this time.

The Trustees are pleased to report that a new corporate sponsor has been secured during this period. INFINITT, a South Korean PACS company, have agreed sponsorship of $20,000 for a 15-month period, October 2020 – December 2021.

Transforming the ICIS Interactive Masterclass series to virtual delivery online has enabled a continuing surplus to be generated by these courses. In view of the excellent feedback to the online format, it is anticipated that online delivery of some courses will continue in the future, alongside a programme of classroom courses provided pandemic restrictions permit in-person attendance.

Cancellation of the ICIS 2020 annual teaching course has exacerbated the financial impact of the pandemic on the Society. The Trustees are conscious that the pandemic will prolong economic constraints and present an additional challenge when securing commercial sponsorship of future annual teaching courses, also potentially affecting the number of delegates registering.

The Society journal Cancer Imaging is a significant element of the Society's overall success. Terms of the new contract with BMC include payment of royalties to the Society based on revenue from published articles. Securing this annual income is welcomed as a further income stream for the Society.

An annual bonus payment is included in the new contract; this is dependent on achievement of pre-determined targets. The option to apply a surcharge to the Article Processing Charges (APC) remains, the proceeds of which would provide direct additional income for the Society from each article published. However, it is important to remain mindful of the potential impact this could have to limit the journal's attractiveness to authors or reduce the number of submissions.

The overall outcome to the year ending 28 February 2021 shows a reduction of Society reserves, with this loss successfully minimised despite the challenges faced during this financial period, and the substantial impact of the pandemic on all aspects of the Society. However, the Society reserves remain strong, the loss incurred has not affected the Society's ability to continue operating, and the medium-term future of the Society is assured. The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation to redress this loss.

Reserves Policy

The Society's policy is to strive to build and hold reserves sufficient to confidently plan to run at least two future annual teaching courses, our main income stream, and be able to provide cover for one failed teaching course. The Society had reserves of £319,546 that were not invested in fixed assets at the year end to February 2021; (2020: £343,228).

Plans for the future

The pandemic has generated additional focus on very careful review of future Society activity. This includes potential ways of expanding the educational portfolio of the Society, reaching additional colleagues in the radiology community internationally and ensuring a stable financial future to permit further growth and development. Globally there has been a shift to virtual meetings and the Society has had to adapt to this new method and cope with new expectations of the international audience. The ongoing pandemic has prolonged restrictions in international travel, necessitating further review of plans for teaching courses and meetings. At the Executive Board meeting in February 2021, it was agreed that all activity should be delivered online throughout 2021.

The second *ICIS in Focus* meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging will be held online 22-24 July 2021, once again in collaboration with the Champalimaud Foundation. This is intended as a non-profit meeting; however, a small registration fee will be charged to defray the costs of organising the virtual meeting. Any surplus generated will be set aside to cover travelling costs of faculty participating in future meetings.

The 2021 annual teaching course will be delivered online over four days, 19-22 September 2021. Careful consideration was given to conducting this course in a hybrid format but on balance, it was felt prudent to plan this purely online and deliver an attractive programme, timed to capture the maximum live online participation from a wide range of geographical locations, whilst also being accessible worldwide through subsequent availability of the course content. The registration fees will be set at an appropriate rate to cover the costs of facilitating an online meeting and achieving a surplus from a relatively low number of delegates compared to that normally expected for a London-based annual course. We will work with the meeting sponsors to maintain their interest and support, with due acknowledgement and facilitating good sponsor visibility within the online setting.

The President for the annual teaching course in 2022 is based in Boston, Massachusetts, USA. The intention has been to arrange this as the Society's first annual teaching course to be held in the USA. Plans will be carefully reviewed to assess any ongoing impact of the pandemic and consideration given to running this as a hybrid or virtual course. It was previously hoped that company support would be at a higher level in the USA but this may be impacted by the economic fallout of the pandemic; the overall financial projections for the conference will be carefully monitored to ensure financial viability.

The Society constantly strives to improve the educational offering of each annual teaching course and the ICIS Interactive Masterclass workshop series. Ideally, attracting the maximum possible number of paying delegates and appreciable sponsorship should generate sufficient income to offset the annual costs of the administrative structure and add to reserves. Plans are underway to expand the ICIS Interactive Masterclass portfolio with the development of new courses covering renal/adrenal tumours and head and neck tumours. It is anticipated to develop these as classroom courses in the first instance before potentially migrating to online delivery.

An e-learning platform is being explored with the proposal to introduce self-directed e-learning modules. Material from retired first edition ICIS Interactive Masterclass courses will be adapted to create modules for independent learning. A charge will be levied for each module, thereby generating an additional income stream for the Society. In addition, a new concept, "Read with the Experts", is also being developed. These seminar style sessions will be planned to accommodate up to 100 participants to review and discuss cases with an ICIS Fellow who specialises in the subject topic. It is hoped to utilise the INFINITT PACS system for these online seminars.

The newly formed sub-committees will work to develop important elements of the Society's offering and provide the opportunity to focus attention and encourage growth in each of these areas, with the intention of generating the Society's international reach and income.

The opportunity to reintroduce satellite meetings will be kept under review as these present an opportunity to enhance the international profile of the Society, enabling radiologists in a range of locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows. A financial appraisal of any proposed venue is reported to the Trustees to ensure no financial risk is posed to the Society. The Society does not cover any of the speaker expenses; these costs must be met by the host societies or personally.

Marketing the Society, meetings and online journal remains a priority; electronic means and social media are used to enhance communication with members and the wider international community with an interest in oncological imaging. Developing further membership benefits will be very important in the coming years, with an emphasis on online education. Google analytics of traffic to the ICIS website permits review of activity and the number of members is monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion.

Risks

The introduction of the risk register is enabling regular review by the Executive Board of any potential risk the Society may face. The Trustees continue to be aware of the financial impact on Society reserves of the administrative structure of ICIS, and overall plans for the Society, including plans to develop the e-learning programme. Establishing ways to generate additional income streams and promoting the Society worldwide remain a top priority. Proposed developments will be reviewed to ensure that the perceived benefits would outweigh the possible risk to the Society, which needs to maintain a viable, modern structure from which to operate and develop.

The sudden global increase of online educational activity in a very competitive virtual environment poses a new challenge and risk to the Society. Whilst migrating activity to online delivery, it is important that the Society's reputation is maintained as a provider of high-quality education on oncological imaging, with articles published in Cancer Imaging supporting retention of the journal's international standing amongst other journals providing sound research articles and reviews. Enhancing the value of ICIS membership will mitigate the risk of diminishing member numbers, whose support is an integral element of the Society's continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series. The financial implications to the Society of any proposed Satellite meetings are carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of Cancer Imaging will be kept under regular review.

The Trustees also take into consideration potential disasters such as floods, fires, earthquakes, volcanoes, international instability and terrorism that could affect plans for Society teaching courses, particularly those planned as in-person events. The risk posed by infectious diseases remains under stringent review in the light of ongoing international instabilities posed by the COVID-19 pandemic. This will be monitored closely to ensure any potential risk to the Society is assessed in detail and precautions taken as necessary. The Executive Board will continue to keep all these risks under review and report to the Trustees. The city and venue for the Annual Teaching Course is chosen very carefully and where possible, a break clause is included in the venue contract to mitigate these potential risks. Insurance is reviewed every year.

By order of the Board on 17 September 2021



Trevor Pereira
Secretary

INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF
INTERNATIONAL CANCER IMAGING SOCIETY

I report to the charity trustees on my examination of the accounts of the Company for the year ended 28th February 2021 set out on pages 11 to 16.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charites Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102)

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Paul Newton FCA
Jacob Cavenagh & Skeet
5 Robin Hood Lane
Sutton
Surrey
SM1 2SW

Date: 4 October 2021

INTERNATIONAL CANCER IMAGING SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account)
FOR THE YEAR ENDED 28TH FEBRUARY 2021

	Note	*Unrestricted 2021* £	*Unrestricted 2020* £
Income from			
Charitable activities			
Conference sponsorship and funding		37,848	92,551
Revenue from conference delegates		-	126,952
Membership income		20,686	15,046
ICIS Interactives		36,674	23,194
Journal income		17,039	-
Other income		397	-
Interest receivable		2,825	952
Total income		115,469	258,695
Expenditure on			
Charitable activities			
Conference costs		5,868	103,345
Design, production and advertising		1,051	8,275
Administration			
- Data Manager		13,018	9,897
- Events & Marketing, and General Manager	6	67,829	67,017
- Administrative Manager		-	31,782
- Secretarial services		-	1,230
- Other		70	-
Pension Scheme		310	292
Travel and accommodation		104	11,897
Printing		4,760	8,818
Bank charges and credit card charges		997	1,917
Gifts and donations		-	946
Insurance		-	690
Accreditations		-	(68)
Postage/delivery charges		462	2,529
Telephone		65	323
Depreciation		306	311
Software expenses		921	131
IT support		1,250	800
Expensed equipment		-	8
Rent		988	5,463
Miscellaneous		701	25,000
Licenses and Permits		137	-
Books and Publications		26	-
Subscriptions		13	13
Accounting		33,997	34,352
Consultancy Fee		5,186	6,972
Governance cost: Independent Examiners fees		1,968	1,890
Foreign exchange losses/(gains)		(876)	(1,693)
Total expenditure		139,151	322,137
Net income / movement in funds		(23,682)	(63,442)
Reconciliation of funds			
Unrestricted fund balance brought forward		343,228	406,670
Unrestricted fund balance carried forward		319,546	343,228

The notes on pages 13 to 16 form part of these financial statements.

INTERNATIONAL CANCER IMAGING SOCIETY

BALANCE SHEET
AS AT 28TH FEBRUARY 2021

	Note	2021 £	2021 £	2020 £	2020 £
Fixed assets					
Tangible fixed assets	2		1,078		935
Current assets					
Debtors	3	17,836		-	
Cash at bank and in hand		366,269		376,187	
		384,105		376,187	
Creditors: Amounts falling due within one year	4	65,637		33,894	
Net current assets			318,468		342,293
Total Net assets less current liabilities			319,546		343,228
Unrestricted Funds	5		319,546		343,228

These accounts have been prepared in accordance with the provisions available to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

For the financial year ended 28 February 2021 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements were approved by the Board on 17 September 2021 and signed on their behalf by:

Prof. Anwar Padhani
Trustee

Prof. Dow Mu Koh
Trustee

Company Registration number: 03908709

The notes on pages 13 to 16 form part of these financial statements.

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guaranteed registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

(b) Going concern

There are no significant uncertainties about the charity's ability to continue as a going concern.

(c) Income recognition

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

(d) Expenditure recognition

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

(e) Irrecoverable VAT

Irrecoverable VAT is included with the expense upon which it is incurred.

(f) Transactions in foreign currencies

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

(g) Tangible fixed assets

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)

1 ACCOUNTING POLICIES (CONTINUED)

(h) Cash at bank and in hand
Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

(i) Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation arising from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are recognised at their settlement amount

(j) Financial instruments
The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2 TANGIBLE FIXED ASSETS

	Computer equipment	*Total*
	£	£
Cost		
As at 1st March 2020	3,806	3,806
Additions	1,150	1,150
Disposals	(3,806)	(3,806)
As at 28th February 2021	1,150	1,150
Depreciation		
As at 1st March 2020	2,871	2,871
Charge for year	306	306
Disposals	(3,105)	(3,105)
As at 28th February 2021	72	72
Net book value		
As at 28th February 2021	1,078	1,078
As at 29th February 2020	935	935

3 DEBTORS

	2021	*2020*
	£	£
Trade debtors	2,131	-
Prepayments and accrued income	15,705	-
	17,836	-

4 CREDITORS

	2021 £	2020 £
Trade creditors	283	3,644
Accruals and deferred income	65,354	30,250
	65,637	33,894

5 MOVEMENT ON FUNDS

	At 1st March 2020 £	Total Income £	Total Expenditure £	At 28th February 2021 £
Unrestricted Funds				
General Fund	343,228	115,469	(139,151)	319,546

	At 1st March 2019 £	Total Income £	Total Expenditure £	At 29th February 2020 £
Unrestricted Funds				
General Fund	406,670	258,695	(322,137)	343,228

6 STAFF COSTS

	2021 £	2020 £
Salaries	63,913	62,413
Pension	1,295	1,368
Social security	2,621	3,236
	67,829	67,017
Average no. staff	2	3

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £41,198 (2020: £35,627). There were no other related party transactions in the year.

7 TRUSTEES' REMUNERATION

None of the trustees received any remuneration from the charity during the year (2020: none). Expenses incurred on behalf of the Society and reimbursed to trustees during the year to 28th February 2021 amounted to £nil (2020: £654 to 1 trustee).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

8 LIMITED BY GUARANTEE

The company is limited by guarantee, each member (termed "Fellow" from October 2004) having guaranteed to pay £1 should the company be wound up.